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This second special Gastein edition of Eurohealth marks an 
important step in the long-standing collaboration between the 
European Observatory on Health Systems and Policies and 
the European Health Forum Gastein in an effort to promote 
a constructive European health policy debate.
With this year’s topic ‘Electing Health –The Europe 
We Want!’ the EHFG speaks to the very core of EU 
health politics. Debating the EU health mandate 
is no stranger to the pages of this journal nor is it 
a new theme for the EHFG. On the contrary, year 
after year the Forum has succeeded in providing 
a unique platform for exploring policy innovations 
and legal developments and for fostering forward 
thinking and decision making among key health policy 
constituencies in the EU. At the risk of sounding 
too optimistic, there is now a sizeable window of 
opportunity to adopt a stronger health policy agenda 
in Europe. While besieged by many challenges, no 
less by the increasing euro-scepticism in politics 
or by the threats posed by the financial crisis to the 
European social model, we believe that many of these 
challenges can be converted into opportunities. 
For instance, we can reassert the uniqueness of 
solidarity as a core European value or demonstrate 
the centrality of health as an engine for societal 
cohesion and economic growth. In the same way, 
the EU counts on an increasing arsenal of legislation, 
policy strategies and instruments to make this 
possible, such as those arising from Europe 2020, 
the European Semester cycle for economic and 
fiscal policy coordination, the Cross-border Care 
Directive or, more recently, the Commission’s 
Communication on effective, accessible and resilient 
health systems. While most, if not all, are born out 
of ‘economic union’ policies with a main objective 
of fostering economic growth, strengthening the 
internal market and supporting financial sustainability, 
they may not offer the sole but perhaps the 
best chance to boost an EU health agenda.
Similar to last year’s edition, the EHFG 2014 poses 
four challenging but very policy-relevant questions to 
its delegates. In a nutshell, we are asking delegates 
to gaze into the crystal ball and share our ‘vision’ 
of: the future of the European social model and its 
core values; the EU’s future role in health and health 
systems; the ‘nuts and bolts’ of implementation 
i.e., what policy frameworks and instruments are 
needed for the EU to fulfil this new role; and, chiefly, 
how the EU can contribute, in practice, to improving 
the performance of health systems in Member States.
The main bulk of the articles in this special issue 
of Eurohealth reflect on the themes of the EHFG 
2014 parallel forum sessions and provide us with 
some very insightful responses. In the lead article 
‘Health and European integration: part of the 
problem or part of the solution?’, Brand and Palm 
address the central question of this year’s Forum 
by placing health at the centre of the Europe 2020 
growth strategy, with the trinity of wealth, economic 
growth and budget sustainability making up its 
constituent dimensions. Without quibbling about 
the ‘holiness’ of such a Trinity, we do agree with 
the authors that the role of the EU in health is 
much broader than that given by the public health 
article in the Treaty. Yet, this should not stop policy 
makers from seeking ways to strengthen the health 
mandate and/or implementing it more effectively, 
such as by championing ‘Health in all EU policies’.
The ‘European Voices’ section provides an 
appetiser for responses from a selected panel of key 
stakeholders in European health policy representing 
the four constituent pillars of the Forum. Notably, with 
the exception of Professor Martin McKee, who shows 
a healthy dose of academic scepticism, all other 
stakeholders including the European Commission, 
World Health Organization (WHO) and the Austrian 
Minister of Health, as well as patients and industry 
representatives, seem to share a fairly positive 
outlook on the future of health in the EU and agree 
on many of the policies that need to be put in place. 
The “Voices from Parliament” heard in this issue 
echo that sense of hope and optimism regarding 
the role of health in European policy-making and the 
priority it deserves in the course of the next term – 
not least for its impact on economic performance.
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These ‘voices’ the universal access health systems as a 
cornerstone of the European social model and a unique strength 
of the EU; a view which is echoed by many of the contributors 
in this issue. Both the papers by Furtado et al (European 
Commission Directorate-General for Health and Consumers) 
and Emiroglu and Kasapi (WHO Regional Office for Europe) 
emphasise its importance in shaping the global health agenda 
and in particular the post 2015 development agenda. Indeed, 
the WHO-led global universal health coverage movement 
joined by many countries, not least the US, underlines the 
important leadership of Europe in this field. If anything, Europe 
is called to play a greater and more assertive role in global 
health governance, and as Furtado and colleagues argue, 
the close collaboration, involvement and support of the EU to 
the WHO global health agenda will be central in doing so.
Perhaps not surprisingly, most contributors to this issue seem 
to sing to the same tune of increasing the EU’s role in health. 
Yet, we cannot criticise them for lack of pragmatism nor for 
‘preaching to the converted’ – a frequent disease amongst 
the public health community. For instance, while Rose argues 
that the EU can, and should, be an agent of change for health, 
she also highlights that it can only do so if ‘it means business.’ 
Referring to the unprecedented opportunity posed by the new 
EU economic governance framework, the article emphasises 
the need to raise the profile of the health commissioner in the 
new Juncker college. The commissioner needs to become a key 
player in the formulation of country-specific recommendations led 
by the Directorate-General for Economic and Financial Affairs.
The articles in this issue provide a particularly rich set of concrete 
examples of the kinds of strategies, instruments and initiatives 
that the EU has at its disposal to fulfil a stronger health role. 
Perhaps, only the most ardent euro-sceptic would disagree 
with the EU putting in place pro-competition regulation or 
promoting innovation in areas such as eHealth or personalised 
medicine – both acknowledged as key for the EU’s economic 
growth. The articles by Leyers et al on ‘Europe’s commitment 
to personalised medicine’ and by Peetso on ‘Telemedicine: the 
time to hesitate is over’ are both excellent illustrations of this. 
Similarly, Furtado and colleagues, in their article on ‘Building EU 
health policy for the future’ demonstrate the benefits of EU-led 
health partnerships with the private sector and civil society. In 
the same way, Czypionka, when asking whether and how to 
reduce the freedom of choice in the new primary health care 
reform in Austria, draws on the wealth of evidence in many other 
EU countries that faced a similar conundrum, thus illustrating 
the benefits of collecting and exchanging rigorous evidence on 
best practice across EU countries. Blümel et al provide another 
example of the shared challenge of assuring high quality care 
while containing costs by illustrating Germany’s latest legislative 
steps towards not only a more transparent system for patients 
but also the introduction of quality-related hospital payment. 
For the 12 former Soviet Union States, on the other hand, 
there are still many hurdles to take on their rocky road towards 
improving the quality of care and population health, which 
according to Rechel et al will necessitate prioritising health on 
government agendas and spurring on health care reforms.
But ultimately, plagiarising John F. Kennedy’s words, we must 
ask ourselves not what the EU can do for us but what we can 
do for the EU to support its health agenda. In that regard, 
Czabanowska calls for a new model of public health leadership 
focused on interdisciplinary collaboration to enable the 
implementation of WHO’s Health 2020 and of a strong EU public 
health agenda. However, we also agree with her in questioning 
how far public health leaders will be willing and able to go in 
adopting these new roles and tackling pervasive and enduring 
health inequalities. While the (lack of) reaction of large parts of 
the public health community to the financial crisis debate has 
not been terribly encouraging, both Ekman et al and Struckmann 
et al emphasise the importance of the expert community 
playing an active role in providing evidence-based research 
to allow for proactive and person-centred policy making.
Finally, the most difficult question posed by the EHFG is tackled 
head-on by Wismar and colleagues in the article ‘What is the 
EU’s contribution to health system performance?’ or, in other 
words, ‘What can the EU add that the Member States have 
difficulties in achieving by themselves?’ which constitutes the 
ultimate stress test for the EU on health. Their article makes a 
strong case for the EU’s positive impact, with many illustrative 
examples such as the ‘country-specific recommendations’ (CRC) 
to reform health systems or the range of legislation on health 
determinants; cross border collaboration, health professional 
mobility and European reference networks. But they also point 
to the challenges posed by the fragmented nature of the EU’s 
action on health, making it difficult for health stakeholders to 
be part of shaping EU health policy, particularly when so much 
decision-making takes place in forums which are not primarily 
focused on health. We underscore their recommendation to 
have an informed debate and explicit decision-making by EU 
leaders on the role of the EU in health and health systems – that 
should serve as a further spur for discussions at the Forum.
In sum, the articles in this issue provide us with a solid 
introduction to the evidence and the issues for those fortunate 
enough to have the opportunity to attend the Forum in the 
idyllic Gastein valley, but also plenty of food for thought for the 
general readership of this journal to move one step forward 
in deciding what is ‘the Europe we really want’ for health.
Josep Figueras Dorli Kahr-Gottlieb
Director,  
European Observatory 
on Health Systems 
and Policies
Secretary General, 
European Health Forum 
Gastein
Cite this as: Eurohealth 2014; 20(3).
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HEALTH	AND	EUROPEAN	
INTEGRATION: PART OF THE 
PROBLEM OR PART OF THE 
SOLUTION?
By: Helmut Brand and Willy Palm
Abstract: The 2014 European Health Forum Gastein will discuss the 
future of the European Union’s health policy after the recent European 
elections and the appointment of a new Commission. Where do we 
stand and what are the real issues at stake? Since the Gastein Forum 
is traditionally based on the idea of bringing together the various 
stakeholders in health, including policy-makers, professionals, civil 
society, industry and academics, we also include initial comments and 
reflections coming from a panel of key stakeholders in European health 
policy on the four questions that will be at the core of discussion in 
Gastein this year.
Keywords: European Union, Health Mandate, EU integration, European Social Model, 
European Health Forum Gastein
Helmut Brand is President of 
the International Forum Gastein 
and Jean Monnet Professor 
in European Public Health, 
Maastricht University. Willy Palm 
is Dissemination Development 
Officer, European Observatory 
on Health Systems and Policies, 
Brussels, Belgium.  
Email: wpa@obs.euro.who.int
Post-electoral stress disorder?
At the end of May 2014, citizens 
from the 28 European Union (EU) 
Member States elected a new European 
Parliament. Despite the attempts to 
increase its political importance and 
strengthen democratic legitimacy of 
EU institutions by linking this election 
with the appointment of the European 
Commission’s President through the 
so-called ‘Spitzenkandidaten’, the 
turnout has remained disappointingly 
low (only 43.09% of eligible voters). 
On top of that, 25% of the seats went to 
candidates from euro-sceptic parties.
All of this seems to indicate a disinterest 
in – if not a mistrust against – the 
European integration project amongst 
part of the European population. As 
also shown in a recent Eurobarometer 
survey, trust in European institutions is 
historically low with an average score 
of 32% (ranging from 18% in Greece up 
to 58% in Romania). 1  However, this is not 
very different from national politics and in 
some cases even much better. As Timothy 
Garton-Ash argued, there are 28 different 
“shades” of unhappiness – many of 
them not even EU-related; however, the 
May 2014 elections are a wake-up call 
from which Europe may fail to wake up. 2 
Clearly, an important factor of 
discontentment has been the financial 
crisis and the way “Europe” has dealt 
with it. The European election campaign 
was dominated by the question of how the 
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ongoing economic downturn, as well as 
the alarming level of youth unemployment 
in certain Member States can be countered 
and how to stabilise the Euro. The political 
debate covered more fundamental issues 
such as the limits of interstate solidarity, a 
more focused mandate for the EU to tackle 
the big problems and a more transparent 
EU serving the needs of its citizens.
Traditionally, the European project has 
stood for peace, prosperity and social 
progress. Now that these noble goals are 
perceived to have reached their limits – or 
these achievements are taken for granted – 
Europe’s cultural, social and political 
leaders are looking for a “new narrative 
for Europe”. 3 
The EU’s health mandate
At first sight, health is not a topic in 
all these discussions. However, in all 
measurements of happiness or quality 
of life, health systematically ranks high 
and it is considered a prime concern for 
many citizens across the EU. 1  Various 
studies have demonstrated the devastating 
effect of the current economic crisis on 
life quality, also through the deterioration 
of health, and the growing inequalities 
and occurring problems of accessibility 
to health care, especially among more 
vulnerable population groups such as older 
people in Central and Eastern Europe and 
the lowest income classes. 4 
Health protection is also considered 
to be intrinsically part of the so-called 
European social model. 5  It is striking that 
when people are asked what values best 
represent the EU, solidarity and support 
for others pop up as defining concepts 
for the European project. 1  So health 
could indeed play an important role in 
reconnecting Europe with its citizens. 
For this we need some kind of “Roaming 
for Health” project. Just like the EU 
effectively addressed excessive roaming 
charges, it could also help to unlock 
resources, knowledge and experience 
in health to the benefit of citizens and 
patients across the EU. This is essentially 
what the European Commission has 
been pushing for within the EU’s health 
mandate since the Maastricht Treaty 
in 1992. However, despite the fact that EU 
actions added positively to various aspects 
of human health protection, some would 
argue that the legal mandate has been too 
weak, the initiatives too diverse and the 
impact too illusive. 6  Due to the “invisible 
hand” of subsidiarity, imposed by Member 
States, EU policy in health could only 
develop in a gradual and fragmented 
way, often in response to “health crises”, 
using a diverse array of – often “soft 
law” – policy instruments. Even though 
in this process EU health policy matured 
to a consistent whole, thanks also to the 
guiding framework of the 2008 health 
strategy, Together for Health, it remains a 
rather small issue on the EU agenda. After 
all, health-related funding through the 
various programmes (research, structural 
funds and the health programme) 
represented only 0.08% of the EU’s budget 
under the previous multi-annual financial 
framework (2007 – 2013).
The Trinity of Health
Still, this is only one part of the picture. 
In reality, EU health policy is much 
broader than the health mandate based 
on the Treaty’s public health article. 7  
Fundamentally, the EU’s approach towards 
health and health systems is threefold 
(see Figure 1). In the first place, health 
is considered an important economic 
sector, representing, on average, 10% of 
GDP and 8% of employment and as such 
is a full part of the internal market. In 
fact, many of the legislative initiatives 
that are of direct relevance to the health 
sector, such as the directives on cross-
border care or professional qualifications, 
are motivated by the principles of free 
movement and based on internal market 
provisions. The second dimension is of 
a budgetary nature. Health expenses 
largely also weigh on the Member States’ 
public budgets and are therefore critical 
in the context of the EU’s economic 
governance that aims to guarantee the 
Union’s economic and monetary stability. 
Through the European semester we 
have increasingly seen country-specific 
recommendations being issued and 
endorsed by the EU institutions to push 
individual Member States to reform their 
health systems and make them more 
financially sustainable. At the same time, 
health is also considered as an important 
factor for economic growth and social 
cohesion. This is why the Commission 
actively promotes the idea of investing 
in sustainable health systems, in people’s 
health and in reducing health inequalities, 
with support from EU funds and as part 
of its social investment package. 8 
Even though these approaches – forming 
the three dimensions of the Trinity of 
Health – may sometimes be perceived 
as contradictory, they all form an 
integral part of the EU’s encompassing 
growth strategy Europe 2020, which 
aims for economic growth that is smart, 
sustainable and inclusive. Still, apart from 
the European innovation partnership 
on active and healthy ageing, positive 
references to health are hard to find in the 
strategy’s priorities, objectives, indicators 
or initiatives. The image persists of an 








Eurohealth incorporating Euro Observer — Vol.20 | No.3 | 2014
7
imbalance in the various approaches. 
Ironically, where Member States often 
continue to claim subsidiarity to deny a 
more direct and positive action for health, 
this does not stop EU economic rules and 
processes from indirectly impacting on 
health and health systems.
Good intentions for a new term
So what to do under the new term? What 
are the priorities that the new European 
Commission and Parliament should 
focus on?
Clearly, as the economic crisis seems to 
turn from an acute into a more chronic 
condition – or as the Greek health minister 
put it at the EHFG 2013: This is not a 
crisis, this is the new reality – the social 
dimension of the EU is to become ever 
more a critical and essential element of 
European integration. The challenge that 
Europe is facing today is nothing less than 
the resilience of its social model. German 
Chancellor, Angela Merkel, recently 
reminded us that in the EU, with 7% of 
the world’s population, we generate 25% 
of the world’s economy but also spend 
nearly 50% of all social benefits in the 
world. To keep this will require a great 
deal of creativity and innovation, she 
concluded. 9  This is exactly what has 
dominated discussions at the European 
Health Forum over the last few years. 
Where in 2012 the main question was the 
effects of the crisis for health, in 2013 the 
focus turned to how health systems can 
be made resilient and innovative.
Next to steadfastness in sticking to the 
values underpinning our health systems, 
we may also need to explore new forms of 
health governance that also better facilitate 
the integration of technological and social 
innovations. Today, no policy level can 
claim any longer full exclusivity over 
health. National, regional and international 
policy-makers will need to work together 
more closely and coordinate their actions 
to achieve better outcomes. This applies 
in the same way to fragmentation and 
duplication within the same policy level. 
In addition, at EU level there is scope for 
better linkages between initiatives that are 
undertaken. For instance, to what extent 
is the valuable work of the Reflection 
process on modern, responsive and 
sustainable health systems, set up in 2011, 
used to inform the country-specific 
recommendations that are issued in the 
field of health system reform? The recent 
Communication on effective, accessible 
and resilient health systems is showing 
the way by compiling all the elements 
available to build a consistent EU agenda. 10
Linked to this, the question that keeps 
cropping up is whether we need a stronger 
health mandate and how this can be 
achieved. Some are suggesting a review 
of the EU’s health strategy. Whereas the 
Commission argues that the strategy 
is still valid since the public health 
challenges it identified back in 2008 have 
not really changed, it could also be said 
that it is a compilation of issues to be 
addressed by the EU rather than a policy 
document setting priorities, assigning 
responsibilities and outlining ways of 
implementation and assessment. Others 
are calling for another revision of the 
Treaty to establish a more solid legal 
base for health action at EU level. 11  As 
appealing as it may seem to push the reset 
button and design a completely new legal 
base for public health in the EU, we should 
be aware of the serious risks connected 
to that option, especially in a climate in 
which the delegation of power back to 
the national level is openly debated to 
compensate for loss of competencies in 
other areas. Hence, any new public health 
article might end up being less powerful 
than what we have now.
Perhaps a more promising strategy would 
be to push for “Health in all EU policies” 
in order to make sure that health impact 
is duly considered when developing 
policy in other areas. In fact, the opening 
of Article 168 provides a clear and solid 
basis for this: A high level of human 
health protection shall be ensured in 
the definition and implementation of 
all Union policies and activities. With 
health impact assessment (HIA) we 
already have an effective tool and a sound 
methodology. It’s just a matter of putting 
this into practice. Moreover, positive 
health impacts should be better marketed 
by the EU: the smaller but important 
advances realised through initiatives, such 
as the joint purchasing of vaccines or the 
European reference networks established 
under the cross-border care directive, 
could pave the way towards a real layer of 
European health care and even – why not? 
– European solidarity.
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In the light of the recent European election outcomes, 
how do you envisage the further development of the 
European social model and its core values?
EU Health Commissioner Tonio Borg does not see in the 
election result a rejection of the European project. Despite 
the crisis, there is still support for a European Union that 
remains united and open whilst seeking to be stronger to 
defend our values and interests. However, the results also call 
for addressing the concerns of those who voted in protest, or 
who did not vote. To Professor Martin McKee this popular 
discontent is due to the failure of the European institutions to 
respond appropriately to the economic crisis. Especially in those 
countries that have been worst affected by austerity, Europe 
is perceived to have prioritised the interests of the banks and 
other financial institutions over those of the people. According 
to EPF’s Executive Director Nicola Bedlington the rise in 
euro-scepticism indicates that the EU must redirect its efforts 
towards concerns that are closer to EU citizens, like health, 
to add value to people’s lives and renew faith in the European 
process. European values of universality, access to good quality 
care, equity and solidarity, safety and patient involvement are 
unfortunately still not a reality for all patients. Disparities 
have been exacerbated by austerity measures. WHO Regional 
Director Zsuzsanna Jakab also hopes that the outcome of the 
European elections may contribute to further promote these 
values. As modern European communities are becoming more 
globally interactive and the health and wellbeing of its citizens is 
becoming dramatically linked to seemingly disparate factors, a 
framework for health to uphold these core values and to ensure 
the right to health for everyone is really needed. Austrian 
Health Minister Alois Stöger reminds us that the Union’s aim, 
as laid down in Article 3 of the Treaty, is to promote peace, its 
values and the wellbeing of its peoples. I am deeply convinced 
that economic and social progress are inseparable. Tackling the 
emerging social challenges in a context of financial constraints 
and demographic pressures requires more than ever a strong 
European social model based on the values of social protection 
for all and solidarity.
EFPIA Director-General Richard Bergström is inherently 
optimistic. With a new generation of politicians in Brussels, 
we have an opportunity to reaffirm what Europe stands 
for. Europe’s social model, for me, has to be at the heart of 
defining what the EU is about. It would be deeply ironic if our 
own commitment to the social model would weaken at a time 
when much of the world is trying to copy the degree of social 
protection – especially in health care – that we have pioneered. 
Also Commissioner Borg thinks it would be hazardous to 
speculate about the effect of this particular election on the 
development of the European social model. I believe that the 
values that underpin our health systems and our action at 
European level are widely shared and stable. Health systems 
form a cornerstone of the European social model and are a key 
component of our efforts to fight the challenges brought upon us 
by the economic crisis and can help addressing people’s current 
concerns. Yet, Professor McKee points to some inconsistencies. 
Take the secretive nature of discussions on the Transatlantic 
Trade and Investment Partnership. Its provision for investor-
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state dispute mechanisms is widely viewed as a means for 
powerful corporate interests to undermine the European social 
model. There is a real danger that the wrong message is taken. 
What is being called for is a Europe that places the interests 
of its citizens first, with the major corporations–whether in the 
financial sector or elsewhere–at their service and not the other 
way round.
After the first 20 years of an EU health mandate, what 
do you consider as its main achievements and what 
vision do you have for the EU’s role in health and 
health systems in the next 20 years?
All interlocutors agree that great progress has been made in the 
area of health at EU level over the last 20 years, even if only 
slowly. Minister Stöger: If you only look at all these measures 
to secure the quality of food products, to protect consumers and 
to secure a healthy environment, we see that important areas 
have been harmonised. Commissioner Borg continues: The EU 
has established a legislative environment benefiting patients 
and economic operators. With the whole body of legislation 
on Organs, Blood, Tissues and Cells, the recent revision of the 
Tobacco Products Directive and of the regulatory framework 
on clinical trials and on pharmaceuticals we have further 
consolidated European health law.
Promoting cooperation between the Member States on health 
policy and on health systems is seen as another important aspect 
of the health mandate. Commissioner Borg: Guided by the 
EU Health Strategy and supported by the successive Health 
Programmes, the Commission supported health systems' efforts 
to address ever growing challenges by fostering cooperation 
and exchanging good practice across Europe on a wide range 
of shared concerns, ranging from addressing lifestyle factors 
over and tackling chronic diseases to capacity building in areas 
such as health technology assessment and health workforce. 
Nicola Bedlington also sees an increasing recognition by 
Member States that EU collaboration is in their interest. This 
has been particularly apparent in the area of patient safety and 
quality of care. Regrettably, we also see signs of disinvestment 
in patient safety in some countries due to financial constraints. 
This is particularly worrying as cutting health care budgets is 
counter-productive and will not contribute to the sustainability 
of health systems in the long run. Richard Bergström agrees: 
The well-documented health consequences of the Austerity 
programmes – where too many blunt instruments were used 
at the expense of genuine efficiency–could have perhaps been 
mitigated had health had a stronger voice in economic policy 
decisions. Martin McKee notes that despite of the EU’s limited 
competence in the field of health, the Commission does have a 
powerful weapon at its disposal. So far, DG SANCO has made 
only limited use of its power to assess the health impact of all EU 
policies, including the impact of austerity.
Commissioner Borg recognises that there is still a long way to 
go to establish a European Union for Health but is convinced we 
should use all means at our disposal to achieve this goal. Take 
for instance the new Joint Procurement agreement on medical 
countermeasures which I have signed with Member States in 
June. Also The Cross-border Health Care Directive that entered 
into force last year is considered a major milestone. Nicola 
Bedlington says: These kinds of measures can have significant 
scope to empower patients and, if implemented properly, they 
can have a transformative effect on health care that is wider 
than the scope of the legislation itself. Minister Stöger warns 
however: We have to proceed step-by-step. The patient rights 
directive was indeed a big step forward for the provision of 
cross-border health services, but now further adjustments of 
the existing processes are needed as well as a re-thinking of all 
involved partners.
Finally, Zsuzsanna Jakab also points to the role of the EU in 
global health. The EU tobacco regulations provide tremendous 
support to the Framework Convention on Tobacco Control 
(FCTC). The EU Decision on serious cross-border threats 
to health put the EU at the forefront in addressing global 
health emergencies and implementing International Health 
Regulations. The EU’s work on environment and health is a 
source of inspiration for other parts of the world. At the same 
time, experiences such as the passage of the Tobacco Products 
Directive provide us with valuable lessons about the activities 
of lobbyists representing powerful corporate interests that seek 
to undermine health, says Professor McKee. More detailed 
research will call for much stronger action on transparency.
In preparation for the next legislative period and 
implementing its Europe 2020 growth strategy, how will 
the current policy frameworks and instruments have to 
be used or reviewed in order for the EU to fulfil its role 
in promoting, protecting and restoring the health of 
its citizens?
For Minister Stöger the top priority of the next legislative period 
will be the recovery of the economy and the radical reduction of 
unemployment. Measures have to be taken to reduce undesirable 
developments in the financial markets, which endanger the EU 
as a whole, but especially social security including national 
health systems. Martin McKee adds: As a modern public 
health physician I must also look upstream and call for reform 
of the flaws in Europe’s financial system that created the 
current problems, coupled with action to redress the otherwise 
inexorable trend in inequality that has recently been explained 
elegantly by Thomas Piketty. Nicola Bedlington confirms: The 
EU should break down health inequalities, striving to make 
treatments available to everyone and encompassing the whole 
care continuum. We need more commitment to Health-in-All 
policies, particular attention to the needs of vulnerable groups 
and investment in key change agents. Also, Richard Bergström 
believes it is possible to not only maintain what Europe has 
now, but to also address some of the glaring inequalities that 
persist. But we may have to start doing things differently, 
forge new partnerships and challenge old silos. In a majority 
of EU countries my industry has entered formal agreements 
with governments to provide stability and predictability of 
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the medicines bill, while seeking to improve access to new 
medicines. Such an approach to partnership could be extended 
to other areas.
Commissioner Borg replies: The Commission has fulfilled 
its role, in full respect of the Treaty and of the subsidiarity 
principle. The Europe 2020 process is currently under review – 
in wide consultation – with new Commission proposals foreseen 
by early 2015. The Commission will need to listen carefully 
to citizens and stakeholders’ views on whether or not health 
outcomes are sufficiently taken into consideration in our current 
strategy and whether more attention needs to be given to the 
link between access to good quality health care services and 
support to the EU’s poverty reduction target. In this respect, 
Zsuzsanna Jakab points to the importance of universal health 
coverage (UHC). UHC is both a means for achieving good health 
outcomes progressively (through full coverage of health services, 
and across all stages of life) and a desirable end in itself (through 
the assurance of protection from financial risk).
As European citizens demand more value for money 
in health care, what can the EU contribute to improving 
the performance and efficiency of Member States’ 
health systems?
Professor McKee is rather sceptical. The role of the EU is even 
more limited with respect to health care than it is in relation 
to health. Perhaps more importantly, there are certain things 
that the EU should not do. European health systems represent 
remarkable value for money. Yet, paradoxically, there are 
frequent calls for more markets in health care, based on 
ideas in use in the USA, the country that spends most among 
industrialised countries and has the worst health system 
performance. Commissioner Borg argues that no health system 
in the EU is sustainable without in-depth reforms. The EU can 
help optimise the way Member States’ health systems work in 
several areas, by pooling knowledge and resources, fostering 
good practice exchange, providing economies of scale in terms 
of analysis and studies, and facilitating access to expert advice 
on health systems reform. This is explained in the Commission’s 
recent Communication on “effective, accessible and resilient 
health systems”. We have to keep fostering innovation and safety, 
not only to ensure high quality standards for health products 
and services but also to support European research excellence 
that benefits patients and boosts the competitiveness of 
industry. Ultimately, these reforms aim at ensuring that Member 
States are able to provide citizens with quality health care for 
generations to come; and as such, to preserve our European 
social model of health care for all.
Minister Stöger agrees that the most important goal is to 
provide a sustainable financial basis for health systems. It is no 
question that measures are needed, to organise health systems 
in the most efficient and effective manner. What we need are 
innovative approaches, including social and organisational 
innovation, to balance future demands against affordable 
resources. Following the thought of subsidiarity, measures 
should be set at the right level. Health systems vary significantly 
between Member States and will continue to do so. Best practice 
models are for sure helpful, but a one-size-fits-all approach 
would not work. There is still much to do and tuning is needed 
but the development goes in the right direction. Also EFPIA 
Director Bergström sees a lot of good progress. In general, 
the trend towards investing in the sort of infrastructure that 
allows the more effective collection, transmission and analysis 
of data should help health care systems make better ‘value-
based decisions’ – not just in medicines, but throughout the 
system. Getting this right in Europe will attract research and 
development investment as well as promote good health policy 
decisions. Europe now needs to think long-term and be creative 
in seeking out solutions to what we know will be a challenging 
few decades.
For Regional Director Jakab the growing burden of non-
communicable diseases (NCDs) presents an immense challenge 
for Member States. Given its close linkage with social and 
environmental health determinants, we know that resolving 
this issue will require a whole-of-society, whole-of-government 
approach and a strong partnership across sectors, as set out 
in our new Health 2020 policy framework. The EU has a major 
role to play in addressing these issues. Nicola Bedlington adds: 
Chronic diseases are seen as a sustainability challenge for 
European health systems. This is usually presented in financial 
terms but it needs to be seen from a patient’s perspective to 
ensure care is designed and delivered around patients’ specific 
needs. Innovation in health care should focus especially on 
the way care is organised and delivered and how it can benefit 
patients. Patients, when involved from the onset, can help 
determine what valuable innovation is to us. As evidence shows 
patient empowerment and involvement is also cost-effective 
and leads to better health outcomes and patient satisfaction. 
She concludes: What is very positive is that today patients 
are recognised as a legitimate stakeholder group and our 
views are sought and increasingly reflected in EU legislation 
and documents.
(*) The reflections and quotes were picked from written contributions received from the various 
panel members to the questions submitted to them. The statements received were organised 
and paraphrased by the Eurohealth editors. 
Eurohealth OBSERVER
Eurohealth incorporating Euro Observer — Vol.20 | No.3 | 2014
11
Eurohealth asked a former, returning and new 
Member of the European Parliament (MEPs) for 
their reflections on the challenges and opportunities 










quality of life 
and addressing 
inequalities in 
access to health 
care and in health 
outcomes are 
key. Challenges include 
tackling poor mental health 
and high rates of suicide 
in some EU countries and 
investing much more in chronic disease prevention, 
but without doubt he argues the highest priority 
should be given by the international community 
to combating multi-resistant bacteria for European 
and global society. This is a threat that Dr Ide, 
as a medical microbiologist & infection control 
specialist, has been aware of for some time.
Austrian MEP, Karin Kadenbach (Group 
of the Progressive Alliance of Socialists and 
Democrats in the European Parliament) has sat 
in the Parliament since 2009 and has served before 
on the EP’s Environment, Public Health and Food 
Safety Committee. She stresses better access to 
health promoting 






to make better 
informed choices. 




and promoted by 
the international 
community. 
Europe will need to achieve further improvements 
to guarantee access to affordable medicines, 
while ensuring that they are safe and effective. 
The important contribution of the European 
pharmaceutical sector to economic growth, 
sustainable employment and wellbeing must 
not prejudice patient safety.
After being an MP and health minister in the UK 
government between 1993 and 1996 John Bowis 
spent a decade in the European Parliament where 
among other things he devoted much attention 
to issues around mental health and cross-border 
care. He believes that it is a time for hope and even 
optimism in health policy making in Europe, so 
long as policy makers give health the priority that 
it deserves. Politicians in Europe must build on its 
health history; understand the crucial link between 
health and wealth; and develop new opportunities 
to transform both. He welcomes recognition by the 
‘semester’ system of the importance of health and 
points to exciting prospects for new health benefits 
for citizens arising from the Cross Border Health 
Care Directive. It opens the way to safe transferable 
prescriptions, to secure transfer of health records and 
to reliable use of telemedicine. As efforts continue to 
identify cost effective solutions, gene research and the 
exploration and development of personalised health 
care and, within that, of personalised medicine, may 




















‘‘ Multi-resistant bacteria will have a huge impact on society in Europe and the world as a whole
‘‘ Preventative measures need to be further developed and promoted by the international community
‘‘ The new ‘semester’ system at long last recognises the part good health can play in improving economic performance and the economic drag that comes from poor and untreated health problems
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BUILDING EU	HEALTH	POLICY FOR 
THE FUTURE
By: Artur Furtado, Georgina Georgiou and Patricia Nelissen
Summary: This article explores policy-making at the EU level in the 
area of health, particularly the importance of partnership relationships 
and taking into account the global dimension of health. One crucial 
aspect is the way that scientific advice feeds into policy-making 
and how that science is effectively translated into policy practice. 
Moreover, the EU’s contribution to the development of global health 
is based on promoting values, norms and regulatory models at 
international level in its regional, bilateral and multilateral relations. 
A number of key questions related to these key health policy 
dimensions will be explored in a session hosted by the European 
Commission’s Directorate – General for Health and Consumers 
at the 2014 European Health Forum Gastein.
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Introduction
To be effective, modern health policy 
needs to involve partners across society in 
policy development and implementation, 
and has to take into account the global 
dimension of health. This is all the more 
relevant at the European Union (EU) 
level. In a session hosted by the European 
Commission's Directorate-General (DG) 
for Health and Consumers at the 2014 
European Health Forum Gastein, a number 
of key questions related to these key health 
policy dimensions are explored.
This article focuses on certain aspects 
of policy-making at EU level in the 
area of health, mainly the way EU 
policy on risk factors and diseases is 
developed and implemented through 
partnerships, globally and with Member 
States and stakeholders. It also explores 
how scientific advice feeds into policy-
making at EU level, including looking 
at some issues related to translating 
science into policy practice. Finally, we 
look at how the EU contributes to the 
development of global health by promoting 
values, norms and regulatory models at 
international level in its regional, bilateral 
and multilateral relations.
Stakeholder involvement: 
not enough, just right or too much 
of a good thing?
While there is broad agreement that 
health is a matter of relevance across 
policies and that its promotion requires 
the commitment of multiple actors, there 
is room for discussion about the place 
of public policy and the right balance in 
the relationship between public health 
authorities and health stakeholders.
➤  #EHFG2014 Forum	2: 
Building EU health policy 
for the future
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Have the public bodies been played by 
industry in the recent past, as some fear? 
Or, quite the opposite, is it the case that 
we need to develop partnerships with the 
NGOs and the for-profit sector to ensure 
faster policy results? Or, perhaps still, 
is the existing cooperation striking the 
right balance? In hindsight, cases of lack 
of regulation are not difficult to identify 
in the wake of the financial crisis. On the 
other hand, examples of poorly devised 
legislation are also easy to come by. How 
much and what type of involvement should 
stakeholders have in the development 
of public policy in the field of health? 
What governance structure should 
frame those contributions? How can we 
better prepare the future, in a realistic, 
practical approach?
‘‘ Scientific Committees: excellence, independence 
and transparency
Interesting examples for this debate may 
be drawn from the EU action on nutrition 
and physical activity. It is framed by 
the 2007 Strategy for Europe on Nutrition, 
Overweight and Obesity-related Health 
Issues  1 , that set up action-oriented 
partnerships involving the Member 
States (High Level Group for Nutrition 
and Physical Activity  2 ) and civil society 
(EU Platform for Action on Diet, Physical 
Activity and Health  3 ). Within the scope 
of the Platform, stakeholders have already 
launched more than 300 voluntary 
commitments. Examples range from 
dedicated newsletters targeting expert 
audiences to a food and beverage industry 
pledge not to advertise to children under 
the age of twelve; a variety of results, from 
basic to excellent, have been achieved. 
What is now the best way forward?
Policies based on science 
and evidence
When preparing its policy and proposals 
relating to consumer safety, public health 
and the environment, the Commission 
relies on independent Scientific 
Committees to provide it with sound 
scientific advice and to draw its attention 
to new and emerging problems. The 
opinions of the Scientific Committees 
are vital for policy-makers to ensure the 
highest level of health and environmental 
protection that European citizens expect 
from the EU institutions. Policy-making 
based on sound science is the main 
principle underpinning risk governance 
and regulation in the EU.
Since 1978, three Committees – the 
Scientific Committee on Consumer Safety, 
the Scientific Committee on Health and 
Environmental Risks and the Scientific 
Committee on Emerging and Newly 
Identified Health Risks – have adopted 
more than a thousand scientific opinions, 
most of which have served as a basis 
for regulations, contributing to a more 
evidence-based EU policy-making. The 
Scientific Committees, whose members 
include eminent scientists from all over the 
world, review and evaluate scientific data 
in order to assess potential risks in a wide 
range of areas. Recent work has focused 
on medical devices, such as the safety of 
PIP silicone breast implants and metal in 
hip replacements, and the health effects 
of electromagnetic fields.
Three basic principles govern the work 
of the Scientific Committees: excellence, 
independence and transparency. An 
open way of functioning is in place to 
continually attract the best scientists 
and to encourage more dialogue with 
stakeholders, with the aim of catalysing 
debate and facilitating exchange of 
information. At the same time, a robust 
set of internal mechanisms is applied 
to safeguard the independence of the 
scientific work and to prevent the risk 
of influence from economic, social or 
other non-scientific grounds. A duty of 
confidentiality applies to information 
that Committee members acquire in the 
course of their work.
Particular attention is given to 
communicating the results of the work of 
the Scientific Committees to ensure that 
their conclusions are known to both the 
scientific community and stakeholders. 
In support of this aim, the entire process 
of the Scientific Committees’ work is 
accessible on a dedicated website (see 
http://ec.europa.eu/health/scientific_
committees/index_en.htm). Moreover, 
several scientific opinions are translated 
into layman language to ensure citizens 
can grasp the core information of 
these opinions.
The need for systematic, best practice risk 
assessment will increase further in years 
to come. The EU will face new challenges, 
in particular the risks posed by new and 
emerging technologies (for example, 
nanotechnologies), as well as from new 
products and services.
Global Health – think global, act 
local, but what to do at the EU level?
Global health is an attractive but complex 
concept that, in capturing and addressing 
the world’s health problems, has come 
to mean all things to all people, with the 
result that no single definition exists (a 
Google search for the term on 4 June 2014 
produced 383 million hits). In 2010, the 
European Commission stated that global 
health is about worldwide improvement 
of health, reduction of disparities, 
and protection against global health 
threats. It went further to acknowledge 
that addressing global health requires 
coherence among internal and external 
policies and actions based on agreed 
principles. There is no doubt about the 
global commitment to improve global 
health, but how can we channel this into 
effective and sustained action? We are told 
to think globally but act locally, but where 
and how can the EU with its policies 
and instruments fit into this paradigm? 
And from what perspective? In its 2010 
Commission Communication on Global 
Health  4 , the Commission considered the 
concept through various lenses, including 
development, trade, security, human 
rights, foreign policy, and governance.
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Analysing global health with a European 
perspective, mindful of EU interests, 
values, expertise and instruments, can be 
approached from three different angles, 
as recently proposed by Kickbusch and 
Szabo  5 : i) global health governance, 
referring mainly to those institutions 
and processes of governance which are 
related to an explicit health mandate, 
such as the World Health Organization 
(WHO); ii) global governance for health, 
referring mainly to those institutions and 
policies of global governance which have 
an impact on health such as, for example, 
international trade or development 
policies; and iii) governance for global 
health, referring to the governance 
mechanisms established to contribute 
to global health.
The EU is a committed supporter of global 
health governance and multilateralism 
and it looks to the WHO for global health 
leadership. The European Commission 
and the WHO have put processes in place 
to ensure good cooperation on a wide 
range of issues at country, regional and 
global levels. The EU, collectively with the 
Member States, is the third largest funder 
of the WHO (behind the Gates Foundation 
and the USA) and participates actively 
in WHO’s governing bodies which set 
priorities and promote the organization’s 
values. In its bilateral relations, the EU 
promotes international health laws, such as 
the International Health Regulations and 
the Framework Convention on Tobacco 
Control and the WHO International 
Code of Conduct on the Recruitment 
of Health Personnel.
But what else can be done? The EU, 
as the world’s first and only regional 
regulator and the world’s largest provider 
of development aid, is a key player in 
addressing major global health scourges, 
including communicable health threats, 
non-communicable diseases and 
humanitarian crises. In this context, it 
works with and at the WHO on global 
health issues.
Looking at the EU’s role in global 
governance for health leads to the question 
of the policy coherence of EU positions 
and an examination of how other EU 
policy areas have direct and indirect 
effects on health, e.g. trade, research, 
development. For example, the proposed 
UN Task Force on Non-communicable 
Diseases has at least 18 UN agencies 
participating. Within the European 
Commission, DG Health and Consumers 
has dialogues with 26 other Commission 
Services on health matters. One policy 
of direct relevance in this context is 
international trade and regulatory 
cooperation. Ongoing negotiations of 
international trade agreements have 
shown the interest of the global health 
community and the need to address 
concerns that have been raised about 
potential negative impacts on health of 
standards convergence and the ability 
of governments to regulate markets for 
the benefit of public health. Another 
example is the global problem of access 
to medicines which is a multi-faceted 
problem – inside and outside the EU – but 
which is addressed in a coherent way 
amongst a range of Commission Services.
‘‘ EU policy areas have direct and indirect effects on health
A third angle focuses on governance 
for global health, by looking at the 
mechanisms and policies designed by 
health authorities, both at EU and Member 
States’ levels, to achieve coherence 
between internal and external policies 
through global health strategies. The 2010 
Commission Communication on Global 
Health looked at four strands of action: 
to establish a more democratic and 
coordinated global governance; to push 
for a collective effort to promote universal 
coverage and access to health services for 
all; to ensure better coherence between 
EU policies relating to health; and to 
improve coordination of EU research 
on global health and boost access in 
developing countries to new knowledge 
and treatments. In recent years, several 
EU Member States have developed 
national global health strategies. It would 
be useful to review how such a strategic 
approach has been developing and 
highlight common goals and values.
The EU and its Member States, as regional 
actors, contribute to global health, not just 
in driving the global agenda or in setting 
global priorities, but also in delivering 
benefits at the local level.
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TELEMEDICINE: THE TIME TO 
HESITATE IS OVER!
By: Terje Peetso
Summary: Considering demographic changes in Europe and higher 
demand for more expensive services, telemedicine would be helpful 
not only because of its effectiveness for prevention, diagnosis, 
treatment and rehabilitation but also because of its cost-effectiveness. 
Telemedicine would be even more effective if interoperability is in place 
as this would allow effective data sharing and analysis which would 
further contribute to better health outcomes. Concerns regarding the 
effectiveness of telemedicine, as well as collection and use of health 
data, have to be addressed in order to make telemedicine part of 
mainstream healthcare.
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Introduction
Telemedicine is defined as “the provision 
of health care services, through the use 
of Information and Communication 
Technology (ICT), in situations where the 
health professional and the patient (or two 
health professionals) are not in the same 
location. It involves secure transmission 
of medical data and information, through 
text, sound, images or other forms needed 
for the prevention, diagnosis, treatment of 
a disease and follow-up of patients”. 1 
In 2008, the European Commission’s 
Communication stated that: “Despite the 
potential of telemedicine, its benefits and 
the technical maturity of the applications, 
the use of telemedicine services is still 
limited, and the market remains highly 
fragmented. Although Member States 
have expressed their commitment to 
wider deployment of telemedicine, most 
telemedicine initiatives are no more 
than one-off, small-scale projects that 
are not integrated into health care 
systems”. 1  Since then the importance 
of telemedicine has been highlighted 
in many documents and initiatives – 
the eHealth Action Plan 2012–2020 
(published together with the Staff 
Working Document on the applicability 
of the existing EU legal framework to 
telemedicine services), 2  the European 
Innovation Partnership on Active and 
Healthy Ageing  3  and in the research and 
innovation programme Horizon 2020 
Societal challenge 1 “Health, demographic 
change and wellbeing”. 4 
Today, with the prevalence of chronic 
diseases increasing, services becoming 
continuously more expensive, demand 
for health and social services increasing, 
and available resources to meet demand 
and expectations shrinking, telemedicine 
would be helpful not only because of its 
effectiveness for prevention, diagnosis, 
treatment and rehabilitation but also 
because of its cost-effectiveness. Studies 
show predominantly positive results, with 
a clear trend towards better results for 
“behavioural” endpoints, (e.g. adherence 
➤  #EHFG2014 Forum	5: 
Deploying eHealth. The time 
to hesitate is over!
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to medication or diet and self-efficacy) 
compared to results for medical outcomes 
(e.g. blood pressure, or mortality), 
quality of life, and economic outcomes 
(e.g. costs or hospitalisation). 5  It is also 
an opportunity to develop innovative 
models and products that will not only 
provide savings and better access to care 
but also opportunities for a new growth 
sector for European health and wellbeing 
entrepreneurs.
‘‘ Concerns regarding use of health data have to be taken 
seriously
However, at the same time, the 
most frequently cited barrier to the 
implementation of telemedicine solutions 
globally is the perception that the cost 
of telemedicine is too high. Almost 70% 
of countries that responded to the World 
Health Organization (WHO) second global 
survey on eHealth  6  indicated the need for 
more information on the cost and cost-
effectiveness of telemedicine solutions, 
and over 50% wanted more information on 
the infrastructure necessary to implement 
telemedicine solutions. Wanting additional 
information on the clinical uses of 
telemedicine was cited by almost 60% 
of countries; it was one of the three most 
requested areas of information. European 
Union (EU) Member States mentioned 
a need for information on clinical 
possibilities, although a lack of knowledge 
of telemedicine applications was not 
considered to be a barrier.
There are two other barriers that the 
EU Member States have highlighted: 
i) organisational culture that is not 
supportive and ii) a lack of demand by 
health care professionals. These can be 
linked to the issues raised in the survey, 
in particular the need for information on 
cost-effectiveness, but it also stresses the 
need for organisational change – the need 
to do certain things in health care systems 
differently; for example, giving more 
responsibility to patients to self-manage 
their diseases. Putting patients in the 
driving seat is also a motto of the eHealth 
Action Plan 2012–2020.
Effectively sharing information about 
the benefits of telemedicine
The Commission has funded many 
projects in the area of ICT for health and 
wellbeing and continues to do so through 
Horizon 2020.  7  This includes specific 
projects on telemedicine such as Renewing 
Health (http://www.renewinghealth.eu/), 
United4Health (http://www.united4health.
eu/) and MasterMind (http://mastermind-
project.eu/). United4Health involves 
approximately 12,000 patients and utilises 
results and good practice from previous 
projects and trials, including the Renewing 
Health project. The services being 
deployed and studied target diabetes, 
chronic obstructive pulmonary disease 
(COPD) and cardiovascular disease. 
The MasterMind project looks at how 
telemedicine can treat depression. It 
is worth underlining that the above 
mentioned projects pay particular attention 
to cost-effectiveness and as such meet 
the needs of many countries that have 
mentioned a lack of this data as an obstacle 
to implementing telemedicine. First results 
from the Renewing Health project are 
expected to be published in Autumn 2014. 
All of these projects pay a lot of attention 
to the dissemination and exploitation of 
results among policy makers, health care 
managers, patients/citizens, insurers and 
health care professionals.
Although, the lack of demand from 
patients has not been highlighted as an 
obstacle to implementing telemedicine, 
there is no doubt that it would certainly 
help its large-scale deployment. Patients' 
concerns regarding the effectiveness of 
such services, as well as collection and 
use of their health data, have to be taken 
seriously and addressed carefully.
First of all, it is important to stress that 
telemedicine is not meant to replace 
traditional medicine and face-to-face 
contact between patients/citizens and 
health care professionals. Key information 
and benefits about telemedicine need 
to be thoroughly explained to patients 
and their carers. In particular, it allows 
the permanent monitoring of patients’ 
conditions, which in turn can improve 
treatment outcomes, prevent unnecessary 
hospitalisation and consequently 
improves quality of life. Turning to data 
management, patients have to be provided 
with a thorough explanation on how 
their health data is collected, stored and 
analysed through the implementation of 
relevant legislation on data protection.
Telemedicine requires 
interoperability
Interoperability is required for the 
efficient collection and analysis of data 
from different technological sources. 
This would improve the efficiency of 
telemedicine not only within one region 
or in an entire Member State but also 
across borders. Lack of national and 
internationally adopted standards is one of 
the obstacles preventing the achievement 
of successful applications of telemedicine. 
Ideally, good practice would include 
the collection of data from different 
sources, facilitating use, for example, 
through patient electronic health records. 
This obstacle was also mentioned by 
many countries participating in the 2010 
WHO survey.
In the eHealth Action Plan 2012–2020 
the Commission recognises the 
importance of working towards achieving 
interoperability within its four levels: 
legal, organisational, semantic and 
technical. The main strategic and 
governance body at EU level for this 
purpose is the eHealth Network set up 
by Directive 0211/24/EU. 8 
Better access, better health care
Although there have been worries that the 
use of information and communication 
technologies in health care will increase 
health inequalities, in fact there is a trend 
towards more positive views on the role 
of these technologies in improving access 
to health care services. For example, tele-
consultation may help in contacting an 
expert in another hospital, town, region 
or Member State for better diagnosis 
and treatment. It may also help people 
with chronic health problems who live 
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in remote areas to be well monitored 
without the need for long-distance travel. 
At the same time, immediate changes 
in treatment plans may be introduced as 
a result of real-time data received from 
daily monitoring systems. This can help to 
avoid a serious deterioration in a patient’s 
condition and the need for hospitalisation. 
According to the Mastermind project, the 
use of telemedicine to treat depression 
has demonstrated a number of advantages 
which include low threshold access 
to proven treatments, both brief and 
more extensive, which, in addition, 
are less expensive.
Conclusions
Introducing new approaches in any 
health care system is not an easy task, 
mainly because this affects the most 
precious thing that we have–our health. 
However, modern technologies have been 
successfully implemented in many areas 
outside health care, as well as within it. 
For example, tele-radiology is already 
part of mainstream health care and 
tele-consultation has become a standard 
procedure for many highly qualified 
doctors. Modern technologies offer many 
good solutions, the implementation of 
which may sometimes need more of 
a change in mind-set than more data 
demonstrating the effectiveness of 
the application.
Indeed, certain issues, such as 
interoperability and data management, 
need to be fully addressed in order to 
achieve the best results for telemedicine. 
However, it is already time to start using 
available telemedicine solutions. The time 
to hesitate is over!
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Health spending continues to outstrip the economic growth 
of most member countries of the OECD. Pay for performance 
(P4P) has been identified as an innovative tool to improve the 
efficiency of health systems but evidence that it increases 
value for money, boosts quality or improves health outcomes 
is limited.
Using a set of case studies from 12 OECD countries (including 
Estonia, France, Germany, Turkey and the UK), this book 
explores whether the potential power of P4P has been over-
sold, or whether the disappointing results to date are more 
likely to be rooted in problems of design and implementation 
































Each case study analyses the design and implementation of 
decisions, including the role of stakeholders; critically assesses 
objectives versus results; and 
examines the “net” impacts, 
including positive spillover 
effects and unintended 
consequences.
With experiences from both 
high and middle-income 
countries, in primary and 
acute care settings, and 
both national and pilot 
programmes, these studies 
provide health finance 
policy-makers in diverse 
settings with a nuanced 
assessment of P4P 
programmes and their 
potential impact on the performance of health systems.
Contents: i) An overview of health provider P4P in 
OECD countries – Health provider P4P and strategic 
health purchasing; P4P programme design; Strengthening 
health system governance through P4P implementation; 
Evaluating P4P programmes; Lessons from the case study 
P4P programmes; ii) Case studies of P4P programmes 
in OECD countries.
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IN HEALTH, EUROPE MUST BE IN 
THE BUSINESS OF CHANGE	AND	
MEAN	BUSINESS
By: Tamsin Rose
Summary: The big challenges for health are clear: the need for a 
major paradigm shift by transforming health care institutions from 
sickness treating systems to promoters of wellbeing. We need to get 
better health outcomes for less resource. Health needs to be a central 
part of all policy-making and an explicit outcome of government 
action. Consumption patterns and behaviour need to change radically 
to reduce the burden of chronic disease. Brussels-based think tank, 
Friends of Europe, sees the new European Commission mandate 
(2014 – 2020) as an opportunity and convened health stakeholders to 
develop recommendations for a new, improved EU approach to health.
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During the summer of 2014, there was 
intense political horse-trading behind 
closed doors between the new European 
Commission President and national 
capitals on the allocation of portfolios. 
Before the new Commission College takes 
office, now is a good moment to reflect 
on what a strongly committed European 
Union (EU) Health Commissioner could 
achieve for health in Europe.
Friends of Europe, a Brussels based 
think tank, convened a Health Working 
Group and brought together a diverse 
group of stakeholders from across Europe 
representing policy-makers at EU and 
national level, international organisations, 
academia, health-related industries and 
non-governmental organisations. The 
Working Group sought to define coherent 
messages from the health community to 
the new Parliament and Commission on 
how they could support positive change 
for health in Europe. The Group met four 
times throughout 2013 and 2014 under the 
Chatham House rules which ensured a 
frank exchange of views and allowed some 
out-of-the-box thinking. The consistent 
theme that emerged was that the EU could 
be the catalyst for some of the major 
transformation that is needed for public 
health and health care but change needs to 
be an explicit EU goal for health. Another 
red thread through the discussions was 
the need to focus on prevention both in 
terms of serious political commitment and 
financial resources.
Strengths and weakness of health 
in Europe
Health is a significant asset for Europe. 
The universal access health care systems 
that exist in all EU countries are a unique 
feature of the region. Life expectancy 
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has steadily risen as living and working 
conditions have improved and most 
citizens can expect to enjoy long periods 
of good health, accessing care when 
they need it. 1  Europe hosts a thriving 
life sciences industry with world leading 
companies that are producing new drugs, 
medical devices and diagnostic tools. 
There is a well-educated workforce readily 
available and funding for health research 
has been ring-fenced, contributing to the 
growing body of scientific knowledge. 
The diversity of health care systems across 
Europe presents opportunities for shared 
learning and exchanges of experiences. EU 
level data collection gives insight into the 
operational efficiency of different health 
systems and allows benchmarking and 
realistic target setting. The EU could and 
should capitalise more on its health assets 
to achieve better health outcomes. 2   3  
‘‘ non-communicable disease burden consumes up to 80% of all health 
care costs
With all good news, there tends to be bad 
news. The societal challenges ahead are 
well understood – demographic change has 
profound implications for health and social 
care costs, chronic diseases consume 
most health care resources but are largely 
preventable. Health care systems are still 
heavily invested in expensive hospital-
based curative services which deliver 
acute care, but are not adapted to provide 
patient-centric care in community settings. 
The poaching of health care staff from one 
health system to another contributes to 
brain drain and both shortages of skilled 
health care workers and skills mismatches 
across Europe. Chronic diseases are 
interrelated, are largely preventable and 
have common risk factors – tobacco 
use, poor nutrition, physical inactivity, 
alcohol consumption, and environmental 
factors. Among the six World Health 
Organization (WHO) regions in the 
world, Europe is the most affected by non 
communicable or chronic diseases. It has 
the highest smoking rates in the world 
for both men (38%) and women (19%). 
Europeans drink more alcohol (12.5 litres 
of pure alcohol per year) than in any 
other part of the world – almost double 
the global average. Only North America 
has a higher proportion of obese citizens 
(26%) than the European region (22%) 
where more than 50% of men and women 
are overweight. In terms of physical 
activity, 35% of the people in Europe are 
insufficiently physically active. So Europe 
scores highly on all the key risk factors 
for chronic diseases. Unsurprisingly the 
resulting non-communicable disease 
burden consumes up to 80% of all health 
care costs in Europe. 1 
Can the EU be an agent of change 
for health?
Change is not easy to achieve and there 
are formidable barriers: the complexity 
of health and care systems, strong 
vested interests and power imbalances 
in the system, information asymmetries 
between users and providers of care, silo 
thinking within health care, short term 
crisis management rather than long term 
strategic planning and legacy health 
care institutions that are out of date and 
unsuitable for modern care models. The 
health care sector has also been slow to 
adopt new technology and therefore has 
not achieved the efficiency gains and 
productivity increases that other sectors 
have benefitted from. Change takes a 
long time in health care; new approaches 
often take ten to fifteen years to become 
enshrined in clinical guidelines and 
ineffective treatment is hard to amend or 
eradicate. Entrenched attitudes by health 
care professionals protecting their own 
interests often block attempts to open up 
areas of care for other types of skills and 
qualifications. The policy environment 
can also be slow to respond when the 
evidence for change is strong – it took 
three decades for politicians to act on 
the link between smoking and cancer. 
Despite the terrible toll that alcohol takes 
on society and the WHO guidance that 
raising the minimum price is an effective 
way of reducing consumption, 4  only 
Scotland has attempted to regulate this 
and has faced strong opposition from 
drinks companies and other governments 
under EU internal market rules. There are 
significant health inequalities in Europe 
which reflect broader inequities in society 
but are exacerbated by prejudiced attitudes 
and poor quality care within health care 
services. The 2013 European Commission 
report on Corruption in Healthcare 
identified problems in some EU countries 
with fraud and informal payments, etc. 
all of which undermine the efficiency of 
the health care system and make it hard 
to reform. 5 
The economic crisis has heightened 
the sense of urgency and sharpened 
the focus on reform of health systems. 
The dramatic drops in Gross Domestic 
Product (GDP) experienced by many 
countries post 2008 has led to deep cuts 
in public spending, including health and 
social services. 6  The new economic 
governance framework gives the EU, 
and particularly the Directorate-General 
for Economic and Financial Affairs 
(DG ECFIN), an unprecedented right to 
critique national investment and spending 
plans. 7  In the past, Member States have 
fiercely defended their exclusive right to 
manage health care systems and therefore 
have been reluctant to actively engage 
at EU level on broader health issues. 
This, in turn, led to health being a low 
profile portfolio within the European 
Commission, and the Directorate-General 
for Health and Consumers (DG SANCO) 
faces many obstacles to being seen as a 
major player in policy discussions.
Raising the profile of the EU Health 
Commissioner
For health to get a seat at the European 
Commission tables where the big picture 
of public financing and health care 
spending is being discussed, it needs 
to have a strong figurehead within 
the European Commission. The ideal 
candidate would be someone who has 
credibility, having served as a Minister 
of Health, and with experience of 
negotiating with Finance Ministries and 
other departments. If they have seniority 
within the Commission, for example 
a Vice President post, they would be 
in a good position to convene groups 
of Commissioners where health is the 
linking theme; for example, consumption/
production patterns, consumer behaviours 
and climate change. To really deliver 
on the disease prevention agenda, the 
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European Commissioner for Health needs 
to take on some big battles. There are 
powerful industries that have shaped the 
environment for consumers, influencing 
behavioural decisions on smoking, 
drinking alcohol or soft drinks and eating 
patterns. They have an economic interest 
in maintaining the status quo and their 
business models would be threatened by 
significant shifts in these consumption 
patterns that are essential to boost disease 
prevention. Other parts of the Commission 
responsible for trade, the internal market, 
industry policy, etc. act as champions 
for these interests and have in the past 
undermined efforts to regulate on the 
basis of public health. The Commissioner 
for Health would need to get fellow 
Commissioners to buy into the vision of 
health as the key outcome of EU actions, 
bringing them alongside when the external 
lobby pressures to block change start 
to mount.
There are some useful policy 
developments that would assist the Health 
Commissioner in making the case for 
change. The utility of GDP as a measure of 
societal progress is being questioned. The 
Organisation for Economic Cooperation 
and Development (OECD) is developing 
the Better Life Index, which is a more 
nuanced basket of eleven criteria to 
measure performance – ranging from 
income and housing to health and work-
life balance. 1  The incoming Commission 
President has promised to invest more 
in social Europe, marking a shift from 
the economic growth driven austerity 
measures. Given the close linkages 
between poverty, social exclusion, 
unemployment and health, this is an 
important development. Poor health 
and chronic illness can be both a driver 
of unemployment and a result of being 
out of the labour market. Health should 
rightfully claim a central space in future 
social Europe initiatives. Health is also 
increasingly acknowledged as being at the 
nexus of climate change, as a contributor 
to the problem (the sector uses resources 
intensively and produces high levels 
of waste) and a consequence of global 
warming as extreme weather events affect 
health and shifting climate patterns bring 
new disease patterns to Europe. Climate 
change will continue to be a headline 
policy priority at EU and global level 
and health should be a central part of the 
debate on how to address it.
Stakeholders’ recommendations 
for EU action on health
Reflecting on these challenges and 
opportunities, a new report from the 
‘Friends of Europe’ think tank (due to be 
published shortly) distils the thinking of 
their Health Working Group’s into a list 
of 23 recommendations on what the EU 
should ‘Start’, ‘Stop’ or ‘Do Differently’ 
during the next mandate. This approach 
was designed to make sure that the report 
did not create an unfeasible list of new 
tasks for the over-stretched European 
Commission staff to take on. The ‘Start’ 
recommendations set out some positive 
steps that the EU could take to reinforce 
efforts to effect positive change for 
health. The recommendations on what 
the EU should ‘Stop doing’ reflects a 
certain frustration with the prior lack 
of coordination and inconsistent follow 
up of initiatives. The ‘Do Differently’ 
recommendations outline how the EU 
could use greater focus and simplification 
with more joined up thinking across policy 
areas to end silo working.
The Working Group was undaunted by 
the size of the challenges facing health in 
Europe and felt that the timing is right for 
a more proactive Commissioner for Health 
who would find allies in the Parliament 
and among Health Ministers that want 
Europe to be a friend to health systems. 
If stakeholders get a clear message at the 
beginning of the mandate that Europe is 
in the business of change for health – and 
it means business – they will find ways to 
align their strategies and activities to this 
agenda. This might be the trigger that is 
needed for the paradigm shift for health.
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Summary: Countries throughout Europe are striving to improve 
the performance of their health systems, and their impact on public 
finances is increasingly important. The European Union is playing a 
stronger role than hitherto in this area, with specific recommendations 
to countries on reforming health systems, and investment into health 
systems available from European funds, alongside its broadly positive 
but fragmented impact on health as a whole. As Europe emerges from 
the financial crisis and the strategic agenda of the Juncker Commission 
is developed, understanding the potential impact and contribution of 
Europe to health is more important than ever.
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The policy context
All countries in Europe are striving to 
improve the performance of their health 
systems. Policy-makers are aiming at 
better returns from time, effort and monies 
invested in health systems. They are also 
seeking to eliminate or reduce the waste 
in health systems caused, for example, 
by over- and mal-treatment or the use of 
ineffective or overly expensive procedures 
and products. Needless to say, that in 
times of austerity many countries are 
confronted with growing health demands 
and dwindling public budgets, putting 
extra pressures on them to get more value 
for money.
It is easy to postulate the quest for 
efficiency, but it is harder to define and 
agree on desired outcomes vis-à-vis the 
investment. The Council of Ministers has 
provided some orientation as it established 
specific health systems values in 2006 
that can serve as goals for performance. 
The Council emphasised the “overarching 
values of universality, access to good 
quality care, equity, and solidarity” and 
“operating principles” of quality, safety, 
evidence and ethics, patient involvement, 
redress, and privacy and confidentiality. 
In other words, health system performance 
would be assessed against the ability to 
serve the whole population, to extend life 
expectancy and improve health-related 
quality of life, to do so regardless of 
social status and to distribute the burden 
of health care funding in a fair manner. 
These Council conclusions have no 
binding character. They were developed 
in the context of a wider debate on cross-
border patient mobility in which Ministers 
of Health were eager to clarify that health 
systems objectives are separate from other 
sectors’ policies and objectives. 1 
➤  #EHFG2014 Forum	6: 
Health System Performance
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Efficiency and health system performance 
increasingly play an important role for 
the European Commission. In 2010 
the EU started to send Member States 
country-specific recommendations (CSR). 
These CSRs are part of the European 
Semester, a form of fiscal governance, 
designed to contribute to fiscal discipline 
and economic recovery in a crisis-
ridden Europe. The recommendations 
made on health systems focus largely 
on financial sustainability and are 
pushing for structural reforms to improve 
efficiency. Within the Commission, the 
Directorate-General for Economic and 
Financial Affairs (ECFIN) is leading 
the development of the CSRs, but the 
conceptual basis of the assessment is not 
entirely clear. Recently, as mandated by 
the Social Protection Committee, the 
Directorate-General for Employment, 
Social Affairs and Inclusion (EMPL) has 
started developing a Joint Assessment 
Framework for health systems in the 
context of the Open Method of Co-
ordination (OMC) but also with relevance 
to the CSR. This framework focuses on 
access, quality, efficiency and contextual 
factors, including equity-related factors, 2  
and is therefore not so dissimilar from the 
values and principles suggested by the 
Council of Ministers.
In the context of the social investment 
package designed to contribute to 
economic recovery in Europe, the 
Commission is also aiming to address 
the needs of health systems. It is making 
the case for investment in health and 
pointing at various areas where Member 
States can improve the efficiency of health 
systems. Among the suggestions are 
many examples for raising health systems 
performance: “using financial incentives 
to encourage patients to register with a 
general practitioner (GP) or family doctor, 
[…] introducing activity- and/or quality-
based payment for diagnosis-related 
groups, […] ensuring a more balanced mix 
of staff skills, […] reducing unnecessary 
use of specialists and hospital care, […] 
better health promotion and disease 
prevention in and outside the health sector, 
[…] improving data collection, [… ] 
using health technology assessment more 
systematically, [… and] the use of less 
expensive equivalent (generic) drugs”. 3 
What is the European Union’s 
contribution to health systems 
performance?
The EU is not just making 
recommendations on how to improve 
health system performance. The EU has 
in some policy areas exclusive or shared 
competencies allowing for legislating 
and adopting legally binding acts. It is 
therefore shaping–or helping to shape–
policies that impact on health and health 
systems and their performance. And this 
impact is bigger than one may think. 
There are several health-related articles in 
the Treaty on the Functioning of the EU 
(art. 168 public health, art. 169 consumer 
protection, art. 191 environment, art. 153 
working environment). These articles 
provides the legal mandate for Community 
action on tobacco, alcohol, environmental 
determinants, climate changes, diet, 
nutrition and physical activity, health 
and safety in the workplace, consumer 
protection and communicable diseases. It 
also includes information, comparison and 
benchmarking and actions on substances 
of human origin. The intensity and 
instruments chosen to tackle these areas 
vary greatly, but the actions are very 
relevant with regards to unburdening 
health systems from diseases amenable 
to prevention and health promotion – 
one way to strengthen health system 
performance. 4 
‘‘ The EU is helping to shape policies that impact on health
A more indirect but often more 
substantial impact on health system 
performance is caused by the internal 
market, the coordination of social 
security systems, and fiscal governance. 
The so-called four freedoms – the free 
movement of goods, services, people 
and capital within the EU’s internal 
market – is also the free movement 
of pharmaceuticals, medical devices, 
diagnosis and therapy and patients. 
This includes a plethora of specific 
issues like procurement, competition law, 
cross-border collaboration, European 
reference networks, e-health, European 
prescription, just to name a few, which 
have, undoubtedly, an impact on health 
system performance.
The EU has various instruments to 
implement these policies, programmes 
and actions.
Directives: The Directives on the 
recognition of professional qualifications 
(health professional mobility), the 
Directive on patient rights in cross-border 
health care and the tobacco products 
Directive are examples of key legislation 
with major impact on health and 
health systems.
Agencies: There are plenty of agencies 
working in health-related fields: the 
European Centre for Disease Prevention 
and Control (ECDC), the European Food 
Safety Authority (EFSA), the European 
Medicines Agency (EMA), the European 
Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), the European 
Environment Agency (EEA) and the 
European Agency for Safety and Health 
at Work. (With a slightly different legal 
status, there is also the Consumers, Health 
and Food Executive Agency (CHAFEA).
Joint action (JA): JAs are a way of 
collaboration between Member States, 
their competent authorities and the 
Commission. Examples under the 
health programme are the JA on Health 
Inequalities, 5  JA on Health Workforce 
Planning and Forecasting  6  and the JA on 
Comprehensive Cancer Control. 7 
Budgets: There is the health programme 
budget, although this is rather seed 
money in comparison with the more 
substantial budgets of the Cohesion policy. 
In addition, the health-related funds of 
the Horizon 2020 research programme 
contribute to health.
Fiscal governance: The European 
Semester, an annual review cycle, holds 
together a host of surveillance, assessment, 
benchmarking and recommendation 
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mechanisms based in a consciously 
expanding base on economic policies 
aimed at controlling public budgets.
Clearly, the EU has the mandate and 
instruments to impact on health and health 
system performance. But is there really 
sufficient policy consistency and is it 
focusing on the key issues?
‘‘ The fragmented nature of EU action on health makes it difficult 
to gain an 
overall picture
Electing health – electing 
performance?
With the recent European Parliament 
elections, fundamental discussions on the 
future direction of European Integration 
entered the political centre stage 
sometimes resulting in strictly opposing 
positions. Big themes like peace, economic 
growth, sovereignty and democracy were 
brought forward in the debate. These 
are certainly key themes; however, if we 
want to do justice to health systems and 
their specific goals, if we are to ask what 
benefits health systems performance, we 
would look at the EU and health from a 
more functional, if not technocratic angle: 
what can the EU add that Member States 
have difficulties to achieve by themselves?
Reviewing past contributions, the EU 
has clearly helped to improve health by 
addressing environmental determinants; 
European citizens are amongst the best 
protected in the world in terms of exposure 
to chemicals or pollution, for example. 
The EU has made progress in addressing 
key social determinants, such as health 
and safety at work, but the impact of wider 
social inequalities on health remains. This 
cannot be blamed on a lack of legal powers 
to act (unlike health, the social powers in 
the Treaty are wide-ranging), but rather on 
a clear preference by national governments 
to address social issues domestically, 
rather than at European level, and 
likewise to keep the overwhelming 
weight of financial tools under national 
control. The EU has also made some 
progress in addressing the behavioural 
determinants of health, but most strongly 
for smoking. For diet and exercise or the 
particularly European issue of alcohol, 
European action has been broadly limited 
to providing information and leaving 
choices to individuals.
This broadly positive impact is not widely 
understood, though. The fragmented 
nature of the EU’s action on health – being 
taken across a wide range of legal bases, 
many of which do not have health as 
an objective – makes it difficult to gain 
an overall picture. This consequently 
makes it difficult for health stakeholders 
to be part of shaping the EU’s health-
related discussions, when so much of the 
discussion and decision-making takes 
place in forums which are not primarily 
focused on health. The qualitative nature 
of much European health cooperation – 
building networks, providing comparable 
data for benchmarking, sharing good 
practice – has done a great deal to improve 
health, too, but works in ways that are 
hard to quantify and demonstrate. Often, 
EU activity based on internal market, 
competition, or trade law has received the 
attention – justly, as in the cases of EU 
action on trade in essential medicines or 
cross-border patient mobility.
Meanwhile, the development of EU fiscal 
governance is potentially important but 
it is difficult to say how much, or what, it 
will mean for health services. In response 
to the fiscal crises of various EU Member 
States after 2008, the EU strengthened 
its existing fiscal governance regime in 
order to more effectively monitor Member 
States’ fiscal policies, economic situation, 
and policies that might in the future lead to 
imbalances. Given the public expenditure 
of health systems, it is no surprise that 
fiscal governance mechanisms start to 
make recommendations about health 
system reform. It remains to be seen how 
effective the fiscal governance system, 
notably the European Semester, is at 
changing health policies or stabilising 
economies for growth, but it is worth 
following.
It is therefore overdue to have an informed 
debate on the achievements and prospects 
of the EU in health and health systems 
and on the appropriate areas of, and 
instruments for, action. Only if we are 
prepared to asked these questions on the 
linkages between EU and health can we 
make informed decisions on electing 
health and improving health system 
performance at European and Member 
State level.
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Summary: It is crucial to accelerate efforts along the last mile of the 
race to meet the Millennium Development Goals (MDGs) in order to 
achieve the goals in the areas where progress is lagging behind. The 
unfinished agenda of the MDGs, noncommunicable diseases, sexual 
and reproductive health and rights and Universal Health Coverage, 
should be addressed in the post-2015 development agenda, through 
a holistic and inclusive approach, based on the concept of well-being 
and not merely the absence of death and disease. Health 2020: the 
European policy for health and well-being will set the ground for 
implementing this new vision in the region.
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Introduction
“Better health for Europe” across 
the 53 countries in the World Health 
Organization’s (WHO) European Region 
is the common priority for WHO and its 
Member States, and collective efforts 
are needed in order to sustain the health 
gains that have been made so far, and to 
ensure the highest attainable standard of 
health, as one of the fundamental rights 
of every human being across countries 
and populations.
Across Europe and Central Asia, health 
has greatly improved in recent decades and 
countries have made significant advances 
towards the Millennium Development 
Goals (MDGs). 1  However, areas remain 
in which action has stagnated and health 
inequities persist between and within 
countries in the region. For example, there 
is a sixteen year gap between the lowest 
and highest life expectancy rates at birth 
and there are marked gender differences. 
Ethnic minorities, some migrant 
communities and groups of travellers, 
such as the Roma, continue to suffer 
disproportionately from preventable and 
treatable diseases.
The “unfinished business” of the MDGs, 
the rapid growth of non-communicable 
diseases (NCDs), disabilities and mental 
health disorders, environmental health 
risks, and the need to improve public 
health capacities and strengthen health 
systems under financial constraint, all call 
for a new approach to health in the 21st 
century. Many of the initiatives designed 
to propel the post-2015 development 
agenda focus on these challenges. The 
Global Thematic Consultation on Health, 2  
one of a series of consultations convened 
by the United Nations to inform the new 
development agenda, called for new 
goals, which, building on the existing 
➤  #EHFG2014 Forum	7: 
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health-related MDGs, set more ambitious 
targets and focus on sustainable health 
and well-being for all. The Regional 
Consultation, Inclusive and Sustainable 
Development: Perspectives from Europe 
and Central Asia on the Post-2015 
Development Agenda, 3  that took place in 
Istanbul, Turkey, on 7 – 8 November 2013, 
highlighted that: “Any goal on health 
should advocate for a whole-of-
government, whole-of-society and a life-
course approach, crucial for addressing 
the social, economic and environmental 
determinants of health and for the 
well-being of societies at large”. The 
unfinished agenda of the MDGs, universal 
health coverage, NCDs and sexual and 
reproductive health and rights should 
be addressed in the future development 
framework. Finally, Health 2020: the 
European policy for health and well-
being, 4  endorsed by the WHO Regional 
Committee for Europe in 2012, provides a 
framework for action across government 
and society and will set the ground for 
implementing this new vision.
Uneven progress in achieving 
health-related MDGs
Substantial progress has been made in 
reducing child and maternal mortality, 
and morbidity and mortality due to HIV 
infection, tuberculosis (TB) and malaria. 
Progress in many countries with the 
highest rates of mortality has accelerated 
in recent years; nevertheless, large gaps 
persist among and within countries. 5  
The current trends form a good basis for 
intensified collective action and expansion 
of successful approaches to overcome 
the challenges posed, and to achieve 
the MDGs.
Child and maternal health
There has been a steady decline in both 
under-five and infant mortality rates 
across the Region – however, with stark 
inequities between countries and within 
countries. The regional average of the 
under-five mortality rate decreased 
from 34 per 1,000 live births in 1990 to 14 
in 2010. This corresponds to a reduction 
of almost two-thirds, and is very close to 
the 2015 target of 11 deaths per 1,000 live 
births. Regional average infant mortality 
rates also have declined, from 28 per 1,000 
live births in 1990 to 12 in 2009. 6   7   8  
‘‘ NCDs account for the largest proportion of mortality
The European regional average maternal 
mortality decreased from 44 per 100,000 
live births in 1990 to 20 in 2010. 9  Despite 
the progress, the European regional 
average mortality decline of 3.8% is short 
of the 5.5% needed to reach the MDG 
target 5A. In Central Asia and Caucasus 
the annual decline is even less (2.1%). 
In addition, there are big discrepancies 
between and within countries, with rates 
ranging from more than 75% above to 
more than 60% below the regional average.
HIV/AIDS
HIV remains a serious public health 
challenge in the region. Newly reported 
cases of HIV continue to increase in 
the region, while globally, the number 
of people newly infected with HIV 
is decreasing. The total cumulative 
number of people (ever) diagnosed and 
reported in Europe is over 1.5 million, 
including 131,000 new HIV cases in 2012. 7  
The gains in HIV treatment are unevenly 
distributed. In the east, antiretroviral 
therapy (ART) coverage remains low, 
with relatively few people who are eligible 
actually starting ART (35%) and achieving 
viral suppression. As a result, the number 
of AIDS cases and deaths due to AIDS 
are increasing. In the west, where ART 
coverage is high, the numbers of cases 
and deaths are decreasing.
The HIV epidemic in the WHO 
European Region is concentrated in 
socially marginalised populations: 
people who inject drugs and their 
sexual partners, men who have sex 
with men, sex workers, prisoners and 
migrants. Strategic information about 
the epidemic has become increasingly 
available and of higher quality. However, 
even though an increasing number of 
countries are adopting evidence-informed 
policies for preventing HIV among key 
populations, implementing harm reduction 
interventions and programmes targeting 
prevention of sexual transmission in 
national AIDS plans remains a challenge 
for many.
Tuberculosis
TB is still a major public health problem 
in the WHO European Region with an 
estimated 350,000 new cases and more 
than 35,000 deaths occurring every 
year, 10  of which more than 80% are in 
Eastern Europe. The major burden in the 
region is constituted by eighteen high-
priority countries with 85% of TB cases 
and more than 99% of all multi-drug 
resistant (MDR)-TB cases. The burden 
varies between and within the countries, 
from a range of less than one TB case 
per 100,000 population to about 160 
TB cases per 100,000. There are also 
large differences in TB rates within the 
countries, including in Western Europe, 
where TB rates can vary up to several 
times higher in some districts of capital 
cities compared to other districts.
In the last decade, TB incidence has 
been falling at an average rate of 5% per 
year, which is the fastest decline among 
WHO regions. In 2012, the estimated 
TB prevalence was 56.4 per 100,000 
population, with an average decline 
rate of 7.7% during the last decade. If 
the downward trends continue, it seems 
feasible that the MDG 6 target of a 50% 
reduction in incidence and prevalence 
by 2015, against the baseline of 1990, 
will be reached. However, with regard to 
mortality, the current modest decline – an 
estimated 36,000 deaths due to TB, equal 
to 3.9 deaths per 100,000 population 
reported in 2012 – suggests that the target 
for halving mortality will not be achieved 
in the region
The WHO European Region has the 
highest MDR-TB rate in the world, with 
fifteen European Member States in the top 
list of 27 high MDR-TB burden countries 
globally. The prevalence of MDR-TB 
among new and previously-treated cases 
amounted to 16% and 45% respectively. 
Treatment coverage for MDR-TB patients 
has increased from 63% in 2011 to 96% 
in 2013; however, the treatment success 
rate for MDR-TB patients is 48.5%, far 
below the target of 75%.
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Growing burden of NCDs and 
mental health
Today, NCDs account for the largest 
proportion of mortality in the WHO 
European Region, accounting for 
about 80% of deaths in 2008. Three main 
disease groups (cardiovascular diseases, 
cancer and mental health disorders) cause 
more than half the burden of disease 
(measured using disability-adjusted life-
years – DALYs).
The determinants of these conditions 
are complex and involve both individual 
and societal factors. Individual variation 
in susceptibility and resilience is in part 
genetically determined, while the social 
determinants – the circumstances in which 
people are born, grow, live, work and age – 
are largely influenced by inequities in the 
distribution of power, money and other 
resources. In particular, socioeconomic 
status in early life greatly influences later 
susceptibility and experience of disease.
The economic impact of these conditions 
threatens to overwhelm health systems in 
many countries in the region. For example, 
cardiovascular diseases cost the European 
Union (EU) economies an estimated 
€192 billion per year. 11  There are growing 
costs to the health care system, but also 
broader effects: absenteeism at work, 
decreased productivity and increased 
employee turnover. Individuals and 
their families face reduced income, 
early retirement, increased reliance on 
welfare support and a burden of direct and 
indirect health care costs, while the state 
faces huge losses in taxes from both lack 
of employment and reduced consumer 
spending.
Public health capacities and health 
systems under financial constraint
Strengthening health systems is key 
to improving population health – it is 
an investment in a healthy workforce, 
economic growth and human and 
social development. The requirement, 
particularly at times of economic 
downturn, is for a needs-driven health 
system that improves health outcomes, and 
the protection of access and services for 
low-income and other vulnerable people. 
Universal access provides a benchmark 
for this.
Universal Health Coverage (UHC) and 
access, suggested as the key contribution 
by the health sector to achieving health 
goals and targets and to improving 
population health more broadly, combines 
access to health services (promotion, 
prevention, treatment and rehabilitation), 
the living conditions needed to achieve 
good health and financial protection to 
prevent ill health from leading to poverty. 
Few countries reach the ideal, but all – rich 
and poor – can make progress.
‘‘ Strengthening health systems is keyAcross the region skills and infrastructure are patchy. Coordination between public 
health and health and social care services 
is often poor and financial policies 
and incentives are not conducive to 
effective coordination of care. There is 
variation in clinical practice and a lack 
of evidence-informed pathways for the 
whole continuum of care. Priority and 
expenditure continue to favour acute 
curative services and high-technology 
diagnostics.
Furthermore, many people experience 
out-of-pocket health expenditure that 
places a catastrophic burden on their 
household budgets, raising severe barriers 
to accessing care. This situation has 
worsened during the economic downturn. 
There is now good evidence that long-term 
unemployment is associated with higher 
levels of disease, especially mental health 
problems, and increased mortality from 
suicide, especially among the poor and 
vulnerable. 5  
Faced with these challenges, across the 
WHO European Region, much remains to 
be done. There are powerful arguments 
for “going upstream” to address the root 
causes of ill health, yet investment in 
health promotion and disease prevention 
remains weak. Establishing coherent 
interdisciplinary health care teams with 
effective management is a priority.
National and subnational health policies, 
strategies and plans are vital to ensure a 
comprehensive and structured approach 
to long-term planning and priority setting. 
Health policies must become more 
evidence informed, intersectoral and 
participatory, and leadership transformed 
accordingly.
A development agenda focused on 
health and well-being, and equity
The MDG agenda is an unfinished 
business in the region. It is crucial to 
accelerate efforts along the last mile of the 
race in order to achieve the MDGs in the 
areas where progress is lagging behind, 
and which remain critically important 
today. The unfinished agenda of the 
MDGs, universal health coverage, NCDs 
and sexual and reproductive health and 
rights should be addressed in the future 
development framework.
The Global Thematic Consultation on 
Health concluded that an overarching 
goal for the wider post-2015 agenda 
should recognise health as a critical 
contributor to, and outcome of, sustainable 
development. It should call for a holistic 
and inclusive approach, based on the 
concept of well-being and not merely 
the absence of death and disease. The 
Consultation aimed at maximising 
healthy life expectancy, with the UHC 
being a key instrument in this respect. 
The Regional Consultation Inclusive and 
Sustainable Development: Perspectives 
from Europe and Central Asia on the 
Post-2015 Development Agenda, echoed 
the necessity of taking a holistic approach 
and tackling the social, economic and 
environmental determinants of health.
Moving towards UHC requires strong 
efficient health systems that can respond 
to the full range of health determinants 
and deliver quality services on a broad 
range of country health priorities. Health 
financing systems are required that can 
raise sufficient funds for health, and also 
provide access to essential medicines 
and other supplies and equipment, good 
governance and health information, and 
a well-trained and motivated workforce.
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Setting the ground for the new 
development agenda, Health 2020, through 
its strategic objectives aims to:
•  improve health for all and reduce health 
inequalities; and
•  improve leadership and participatory 
governance for health.
Combating health inequalities and 
achieving the best possible health and 
well-being for all requires a range of 
policy and governance interventions, 
mainly in the following areas:
•  Addressing the social, economic and 
environmental determinants of health 
through intersectoral action and 
integrated policy measures;
•  Tackling environmental threats to 
human health, including those related 
to air quality, climate change, transport 
and water and sanitation. In this regard, 
the European Environment and Health 
Process is critical to shaping appropriate 
policies and actions in the region;
•  Taking a life-course approach to 
increased equity in health, beginning 
early in life (with pregnancy and 
early childhood development) and 
continuing with school, the transition 
to reproductive age, working life, 
employment and working conditions, 
and circumstances affecting older 
people;
•  Intervening to prevent the transmission 
of disadvantage and health inequity 
across generations;
•  Putting in place policies that remove 
gender differences in health and social 
and economic opportunities;
•  Strengthening national health 
information systems, civil registration 
and vital statistics, down to the district 
level and below, as prerequisite for 
measuring and improving equity.
Building the governance required to 
orchestrate a coherent response across 
government and society which results in 
better health outcomes remains one of 
the greatest challenges in global health. 
Addressing the priorities put forward 
by Health 2020: the European policy 
for health and well-being provides a 
framework for action across government 
and society and calls for a combination 
of governance approaches that promote 
health, equity and well-being.
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Although leadership is a well-known 
concept within organisational science, 
public health leadership has still not 
been well-defined. There is a developing 
consensus that public health organisations 
should engage in building leadership 
capacity. To develop effective public 
health leadership therefore requires 
these organisations to actively engage in 
developing more leaders at every level.
A key driver in improving leadership 
within public health is that the nature of 
the challenges faced by such professionals 
is evolving. The combination of a range of 
socioeconomic drivers, including ageing 
populations and workforces, globalisation, 
consumerism and individualism all have 
an effect on health and health-related 
issues leading to increasing health 
inequalities. In addition, modern global 
developments include: over consumption, 
increasing social inequalities and rising 
rates of mental distress and disorder. In 
Europe, these challenges are currently 
exacerbated by the impact of global 
recession and austerity measures that 
have been introduced in many European 
countries, which are putting health 
systems under significant financial 
pressures and forcing them to deliver 
more with diminishing resources. 
Therefore, developing effective leadership 
is essential.
➤  #EHFG2014 Forum	1: 
Public health leadership
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What is public health leadership?
Definitions of public health leadership 
vary from the idea that it includes 
commitment to the community and the 
values it stands  1  for to the argument that 
public health leaders differ from leaders 
in other sectors as they are required to 
balance corporate legitimacy, whilst 
also existing outside the corporate 
environment. 2  A more collaborative 
world will require a new generation of 
leaders in public health with new mind-
sets, an appetite for innovation and 
interdisciplinary collaboration and a 
strong dose of political savvy. 3  A public 
health leader “must be the transcendent, 
collaborative ‘servant leader’ who knits 
and aligns disparate voices together behind 
a common mission.”  4 
‘‘ make decisions in an increasingly complex environment
Public health leaders need to be 
exceptional networker-connectors, 
capable of putting the pieces of the 
puzzle together; they must combine 
administrative excellence with a strong 
sense of professional welfare and actively 
develop the profession, articulate its shared 
values, and build for the future. 5  Today, 
the particular type of leadership required 
is not of a traditional command and 
control variety but rather akin to what has 
been termed adaptive leadership: leading 
in contexts where there is considerable 
uncertainty and ambiguity, and where 
there is often imperfect evidence and 
an absence of agreement about both the 
precise nature of the problem and the 
solutions to it. 6  Professional development 
of public health leaders requires 
competency-based instruction to help 
them develop the abilities to address the 
complex and evolving demands of health 
care systems.
Public health leadership competency 
framework
Whilst considerable work has been 
done in the development of leadership 
competencies in the field of health 
worldwide, these frameworks seem very 
generic and none have been specifically 
developed to support the educational 
curriculum for public health professionals. 
A new model has been developed 
within the framework of the Leaders 
for European Public Health Erasmus 
Multilateral Curriculum Development 
Project (LEPHIE), supported by the EU 
Lifelong Learning Programme. Based 
on a review of public health and public 
health leadership competency frameworks, 
leadership literature and expert review 
panels, the framework was developed 
to support the continuing professional 
development (CPD) curriculum and 
facilitate self-assessment of public health 
leadership competencies.
Competencies are composites of individual 
attributes (i.e. knowledge, skills, and 
attitudinal or personal aspects) that 
represent context-bound productivity. 8  
Fifty-two competencies are distributed 
around nine domain areas, including: 
Systems Thinking, Political Leadership, 
Building & Leading Interdisciplinary 
Teams, Leadership and Communication, 
Leading Change, Emotional Intelligence & 
Leadership in Team-based Organisations, 
Leadership Organisational Learning & 
Development, Ethics and Professionalism. 7  
The Public Health Leadership Competency 
Framework can serve as a useful tool 
in identifying gaps in knowledge and 
skills and shaping adequate competency-
based CPD curricula for public health 
professionals. It is also an attempt to 
define, profile and position public health 
leadership through a systematically 
developed, comprehensive and 
multidisciplinary competency framework 
which can be used by public health 
professionals as a tool for self-assessment 
and personal development planning. 8 
Leadership in the contemporary 
public health context
The results of a recent survey carried 
out by the Association of Schools of 
Public Health in the European Region 
(ASPHER) reveal that it is still not 
common for leadership development to 
be included in European public health 
training programmes. 9  At the same 
time, The Lancet Commission raised 
the question of how higher education 
institutions delivering public health 
education can provide the content and 
context to initiate a major reconsideration 
of working and learning patterns 
which incorporate novel forms, based 
on the principles of inter-professional 
collaboration. 10  In response to this need, 
a model representing the meaning of 
contemporary public health leadership in 
a European context was developed based 
on in-depth interviews with prominent 
European public health leaders  11  within 
the LEPHIE Project.
The interviews were conducted to develop 
an understanding of the nature of public 
health and identify skills needed by 
public health leaders to successfully meet 
present and future patient and population 
health requirements as well as help tackle 
health inequalities. The model consists of 
six themes identified from the interview 
data (see Box 1). This model does not 
reflect a particular leadership theory 
or orientation but presents a picture of 
current public health leadership based on 
the real life experiences of public health 
leaders. However, elements of it resonate 
with aspects of generic theories such as 
transformational leadership, situational 
leadership, and servant leadership. 11 
The content of the interviews showed that 
public health leaders, confronted with 
major shifts in the nature of ill health 
Box 1: Six themes shaping public 
health leadership
• European public health context
• Inner path of leadership
• Essence of leadership
• Emerging styles of leadership
• Future leader’s imperatives
•  Benefiting society and improving 
wellbeing
Source: Reference  11 
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and growing diversity within health 
professions, have to make decisions in an 
increasingly complex environment. To add 
a further layer of challenge, globalisation 
and the economic crisis significantly 
impact on public health functions and 
how to operationally deal with existing 
and emerging health problems. These 
problems establish a strong mandate for 
public health leaders to develop more 
proactive health service models. Public 
health leaders need horizontal, alliance-
based leadership, allowing them to work 
closely with stakeholders at all levels of 
society to effectively meet the challenges 
of population health and well-being. 
They should be driven by values of social 
justice, equity, honesty and responsibility, 
coupled with expertise, ability to discern 
trends in the midst of complexity and 
to capitalise on those trends by creating 
smart, adaptive strategies in an evolving 
environment.
Public health leaders demand leadership 
skills and behaviours that value decision-
making by inclusion, collaboration and the 
broader participation of interdisciplinary 
health care teams engaging all members in 
shared leadership roles and collaborating 
with publicly-led health and equity related 
campaigns. Today’s leaders need to be 
enablers and facilitators who support 
groups in creating and achieving shared 
goals. This principle of leadership is 
reflected in the notion of empowerment 
that is central to health promotion: 
enabling people to improve their health 
and address its determinants. Such 
an approach reflects transformational 
leadership, in which power for change is 
based on goals that serve a higher purpose, 
in this case better health and wellbeing 
as a societal goal. This is the essence of 
the new framework for European public 
health leadership.
Public health leadership training: 
a vision for the future
Since leadership, in general, is still not 
common at undergraduate, postgraduate 
and CPD level of public health education, 
there is a need for providers of public 
health training to practically develop more 
progressive curricula which incorporate 
leadership.
CPD options may be optimised if they are 
collaborative, interdisciplinary, inter-
professional as well as global and digital. 
The CPD course LEPHIE delivered by 
Maastricht University* and developed 
in collaboration with ASPHER, can 
serve as an example of such a training 
course targeted at busy public health 
professionals. Bearing in mind that the 
key to differentiating leadership in public 
health from other areas is the context, this 
course includes current meaningful public 
health problems and challenges which 
participants try to solve by using problem-
based learning methods. Participants 
take responsibility for and plan their own 
learning as they construct or reconstruct 
their knowledge. Learning becomes 
a collaborative process by sharing a 
common goal, responsibilities, and 
learning needs through open interaction. 
The content of the course is based on the 
Public Health Leadership Competency 
Framework, which also serves as a self-
assessment tool in executive coaching 
which supports individual leader 
development and is an indispensable part 
of training to produce effective public 
health leaders.
‘‘ active and inquiry-based learningIn developing the content of other new public health leadership courses, a starting point may be to identify the competency capacities of future leaders in relation 
to population health and well-being 
and apply the results of the interviews 
with public health leaders to inform 
education, training and culture change 
throughout public health workforce. 
Topical cases, active and inquiry-based 
learning processes should be at the heart 
of the learning experience. Participants 
should be encouraged to engage directly 
with community organisations and draw 
on the knowledge sources that inform 
public health theory, policy and practice. 




to face, print and information technology – 
is encouraged as it supports busy 
professionals interested in developing their 
expertise through CPD  11  and facilitates 
transformational learning for health equity.
However, the question remains: who 
should take responsibility for the 
development of public health leadership 
that is fit for purpose, accessible and 
supports the career development path 
of public health leaders?
Developing public health leadership 
capacities
It seems that there is a strong awareness 
among the public health professional 
community – supported by targeted 
policies such as the Health 2020 and the 
WHO European Action Plan about the 
importance of developing public health 
leadership to tackle health inequities and 
inequalities. Moreover, WHO Essential 
Public Health Operations (EPHOs) form 
a framework for the entire public health 
system. In particular, EPHO No. 7 on 
Assuring a sufficient and competent public 
health workforce is a key operation for 
WHO to promote strategies supporting the 
development of a public health workforce. 
At the same time, it provides a mandate 
for developing the adequate and modern 
training in which public health leadership 
can play a prominent role.
In 2013, the WHO Regional Office 
for Europe delegated responsibility to 
ASPHER to lead its working group on 
EPHO No. 7. The development of a public 
health workforce and shaping the public 
health profession is a key action area 
focusing on preparing the public health 
disciplinary cluster to face and respond 
to the health and health care challenges 
of the 21st Century. 12  In this area, WHO 
and ASPHER concentrate on collaboration 
to develop comprehensive educational 
strategies for public health based on the 
systematic mapping of member states’ 
workforce capacities. With direct access 
to public health schools and departments, 
the development and adaptation of public 
health leadership programmes as well as 
leadership competencies have significant 
potential for success.
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Conclusion
The development of strong and effective 
public health leadership is essential at 
all levels. There are examples of public 
health leadership training approaches 
supported by innovative IT and leadership 
competency models which can be adjusted 
to specific contexts and illustrated by 
real-life problems reflecting the struggles 
of public health communities. The 
commitment of key stakeholders in the 
area of policy, education and practice 
to support public health capacities is in 
place. Therefore, the question remains on 
how far new public health leaders will be 
willing and able to go in order to tackle 
pervasive and enduring health inequalities, 
particularly in view of the new post-
election political landscape which may 
see an increasingly conservative and 
Euro-sceptical shift.
References
 1  Rowitz L. Public health leadership: putting 
principles into practice. Sudbury: Jones and Bartlett 
Publishers, 2003.
 2  Grainger G, Griffiths R. For debate: public health 
leadership – do we have it? Do we need it? Journal of 
Public Health Medicine 1998;29: 375 – 6.
 3  Kimberly JR. Preparing leaders in public health 
for success in a flatter, more distributed and 
collaborative world. Public Health Reviews 2011; 
33: 289 – 99.
 4  Koh H. Leadership in public health. Journal of 
Cancer Education 2009; 24: S11 – 8.
 5  Day M, Shickle D, Smith K, Zakariasen K, et al. 
Time for heroes: public health leadership in the 
21st Century. The Lancet 2012 Oct; 380 (9849): 
1205 – 6.
 6  WHO Regional Office for Europe. Strengthening 
Public Health Capacities and Services in 
Europe: A Framework for Action. Interim Draft, 




 7  Loo JV, Semeijn J. Defining and measuring 
competences: An application to graduate surveys. 
Quality & Quantity 2004; 38, 331 – 49.
 8  Czabanowska K, Smith T, Könings KD, Sumskas L, 
et al. In search of a public health leadership 
competency framework to support leadership 
curriculum – a consensus study. European Journal 
of Public Health 2013. doi: 10.1093/eurpub/ckt158.
 9  Bjegovic-Mikanovic V, Vukovic D, Otok R, 
Czabanowska K, Laaser U. Education and training of 
public health professionals in the European Region: 
variation and convergence. International Journal of 
Public Health 2012; DOI: 10.1007/s00038 - 012 - 0425.
 10  Frenk J, Chen L, Bhutta ZA, Cohen J, et al. 
Health professionals for a new century: transforming 
education to strengthen health systems in an 
interdependent world. The Lancet 2010; 375 (9721): 
1137 – 8.
 11  Czabanowska K, Rethmeier RA, Lueddeke G, 
Smith T et al. Public Health in the 21st Century: 
“Working Differently Means Leading and Learning 
Differently” (A qualitative study based on interviews 
with European public health leaders). European 
Journal of Public Health 2014; doi: 10.1093/eurpub/
cku043.
 12  Foldspang A, Otok R, Czabanowska K, Bjegovic-
Mikanovic V. Developing the public health workforce 
in Europe. The European Public Health Reference 
Framework (EPHRF): Its council and online repository. 
Concepts and policy brief. Brussels: ASPHER, 2014.
Facets of public health in Europe
Edited by:  B Rechel and M McKee 
Open University Press: Observatory Studies Series, 2014
Number of pages: 400; ISBN: 978 033526420 9 
Available to purchase at: http://www.mheducation.co.uk/
html/0335264204.html




















 to reducing th











 and cancer, w
hich make up 
the
major disease 




s a broad but 
detailed appro
ach to public h
ealth
in Europe and 
offers the most
 comprehensiv
e analysis of th
is
region currentl
y available. It 
considers a hu
ge range of ke
y
topics in public
 health and inc
ludes chapters
 on the followi
ng
topics:
• Screening• Health Promotion• Tackling social determ
inants of healt
h
• Health Impact Assessm
ent
• The Public Health Wor
kforce
• Public Health Research
In addition to 
these topics an






 and services a
cross
a range of Eur
opean countrie
s; identifying w















n this book use
s examples fro





es to public he
alth.
This book is es
sential reading
 for anyone stu
dying or worki
ng in
the field of pub
lic health, espe
cially those wit






















is Professor of 
European Publ
ic Health at th
e
London School
















In the last two centuries, public health has reduced the impact 
and prevalence of infectious diseases, but much remains to be 
done to reduce 
noncommunicable diseases, 
such as heart disease and 
cancer, which comprise the 
bulk of the disease burden 
on the WHO European 
Region. This book takes 
a broad but detailed 
approach to public health 
in Europe and offers the 
most comprehensive 
analysis of the Region 
available. It considers a 
huge range of key topics 
in public health.
In addition, the authors consider the existing public health 
structures, capacities and services in a range of European 
countries, identifying what needs to be done to strengthen 
action and improve outcomes for public health.
Reflecting the broad geographical scope of the entire WHO 
European Region, this book uses examples from a diverse 
range of countries to illustrate different approaches to public 
health. It is essential reading for anyone studying or working 
in the field of public health, especially those with an interest 
in European practice.
Contents: Introduction; The changing context of public health 
in Europe; Monitoring the health of the population; The health 
security framework in Europe; Occupational health and safety; 
Environmental health; Food security and healthier food choices; 
Health care public health; Screening; Health promotion; 
Tackling the social determinants of health; Intersectoral 
working and health in all policies; Health impact assessment; 
Organization and financing of public health; Developing the 
public health workforce; Developing public health leadership; 
Public health research; Knowledge brokering in public health; 
Drawing the lessons.
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Summary: How will a European high quality health care system – that 
can be afforded by society and still capture the inevitable societal, 
medical and technical progress – look like in twenty years? The 
WE CARE project coordinates the development of a new roadmap 
for Research and Development (R&D) towards 2035 to achieve a 
breakthrough in increasing health care costs while maintaining 
quality of care. The project challenges the European scientific 
community, policy makers and other key players within and outside 
the health care field to get involved and looks into current R&D, 
recently implemented cost containment strategies, and barriers 
to implementation.
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Across the European Union (EU), there 
is a clear and urgent need to curb health 
care costs. Health care spending in the five 
largest economies of the EU has grown 
by 27% from 2005 to 2010. 1  The situation 
is equally alarming in other EU Member 
States. The societal and economic impact 
of this trend is enormous, jeopardising 
the affordability and accessibility of 
health care to all EU-citizens. The biggest 
challenge is to capture the constant 
development of health care, to improve 
quality, and at the same time to contain 
increasing costs. This should ensure 
that all EU citizens have equal access to 
future health care, not only those who can 
afford private solutions. This is simply 
a democratic issue. However, where the 
current European research and policy 
agenda addresses this issue, it is most 
often under the labels of “increasing 
efficiency” (such as changing payment 
systems towards capitation or diagnosis-
related groups) or “value-for-money” (such 
as health technology assessment – HTA), 
but not overall cost containment.
The scientific problem
Containing costs and improving 
health care quality are often viewed as 
conflicting aims. R&D and innovation 
within the health area over the past twenty 
years has led to significant improvements 
in health care but generally have not 
contributed to curbing costs or keeping 
health care sustainable and affordable. 
Moreover, in current research funding, 
not much attention is given to cost 
containment at the macro level.
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Technological, pharmaceutical and 
service-line innovations potentially result 
in better health outcomes and possibly 
more ‘value for money’. Unfortunately, 
reality often shows that instead of more 
‘value for money’, the aggregate costs of 
health care provision to European citizens 
increase. 2  This increase is primarily 
caused by the reactive mechanisms 
in the entire health care system and 
its environment: 1) HTA looks at the 
cost-effectiveness of innovations, but 
is limited to available evidence which 
often concentrates on patients with high 
ability to benefit; 2) after the innovation is 
included in the public benefit baskets, it is 
also “inappropriately” applied to patients 
in which it may not be cost-effective; 
3) this increase in the number of patients is 
fuelled by higher efficiencies of providers, 
made possible by other reforms such as 
new forms of payment; and 4) savings 
are thus not translated into macro level 
savings (i.e. lower total expenditure on 
health care) but end up as extra revenue 
in the hands of the providers.
Therefore, the challenge for WE CARE is 
to define a new strategic plan and R&D 
roadmap that embeds clear and viable 
plans on how science/R&D can facilitate 
a breakthrough in cost containment while, 
at the same time, improving the quality of 
care (which not only considers efficacy in 
clinical studies but also actual provision, 
including the appropriateness of services).
Due to the complexity of the health 
care sector, fundamental knowledge 
of institutional mechanisms, systems, 
methods and paradigms for change are 
needed. The challenge is enhanced by the 
fact that a multi-disciplinary approach is 
a pre-condition to change. The different 
scientific fields are too intertwined to 
allow for a mono-disciplinary approach. 
Cross-sectoral collaboration is therefore 
crucial in opening and supporting the 
innovative potential of non-health care 
disciplines to the benefit of the health 
care sector.
The mechanisms behind the increase in 
cost are complex and not well understood. 
For instance:
–  Demographic change and increases 
in chronic diseases play a role, but are 
not dominant.
–  The health sector is highly fragmented 
and organised along different sectors, 
disciplines and (with regard to R&D) 
diseases. Even though individual 
participants within the sector 
might take limitation of costs into 
consideration, many aspects hinder 
change and prohibit a breakthrough 
in containing costs.
–  Technological innovations play 
an important role and can lead to 
substantial cost reduction but can 
also lead to increased expenditure 
(see above).
–  The financial mechanisms for 
reimbursement, institutional settings, 
the culture within the sector, and the 
lack of a shared responsibility amongst 
participants may cause deficits in the 
national health care budgets across 
the EU.
Is there potential for cost savings?
IBM published the results of a survey 
of 518 economists  3  and concluded that the 
health sector (with an estimated system 
value of $4.27 trillion (€3.2 trillion) has 
the highest percentage of inefficiency – 
estimated to be above 40%. This is in 
line with the estimate by Berwick and 
Hackbarth  4  for the United States of 
around one third. Of this inefficiency, 
the surveyed economists estimated that 
nearly 35% (or c. 15% of total expenditure) 
could be avoided, leading to savings 
or providing room for improvement – 
while the analysis of the American 
scenario suggested that the reduction of 
inefficiencies could be used to keep health 
expenditure at 17.5% of Gross Domestic 
Product (GDP) stable for the next decade 
(instead of growing to more than 20% 
by 2020). Examples of challenges in future 
health care are multi-fold.
‘‘ multi-disciplinary approach is pre-condition to change
Often discussed is the person-centred 
approach where care is tailored together 
with each patient – in contrast to a 
personalised medicine approach where 
every patient’s unique features are 
measured down to proteins and genes. 
As both options are in progress, there 
is a need to define the values of these 
approaches and to find out how they can 
be combined and optimised. Although 
there is substantial evidence on the direct 
effects of policy efforts towards cost 
containment in health systems, it tends 
to be focused on single policies, often 
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in specific settings and whether macro 
level cost containment is achieved often 
remains unclear.
The WE CARE project
The WE CARE project is a two-
year project funded by the European 
Commission’s framework programme 
FP7. The WE CARE Consortium 
is set up in a very diversified and 
multifunctional fashion with seven 
partners. The mission of WE CARE 
is to coordinate the development of a 
new Strategic plan and R&D roadmap 
on cost containment of health care with 
maintained or even improved quality, by 
stepping-up coordination between EU 
key players (see Figure 1). This will be 
accomplished by inviting EU key players 
from politics, industry and academia to 
participate in the project and to contribute 
to the development of the strategy plan 
and a R&D roadmap for 2035, which 
should become part of the EU’s future 
health research.
In a multidisciplinary environment, 
different options to improve health care 
quality and at the same time contain cost 
will be explored. This will cover diverse 
areas of the health care system, like 
organisation of health care on a micro 
level, the use of technology, efficient 
policy-making and optimal reimbursement 
systems. Workshops will be held 
during 2014 with the goal to define a 
number of R&D gaps that can be included 
in the roadmap. In the meantime, the 
consortium welcomes posts and comments 
on the online Forum. On 14 – 15 April 2015, 
a congress will be held in Gothenburg 
to discuss and synthesise the results of 
the WE CARE project and to finalise the 
Strategy Plan and R&D Road Map for the 
future EU HEALTH R&D programme.
Conclusion
The economic and societal relevance of 
this action is enormous due to the high 
impact of health care costs on national 
governmental budgets. If no breakthrough 
in cost containment will be realised in 
due course, health care could become 
unaffordable for many citizens within 
EU Member States. Therefore, health care 
systems in Europe need to be realigned 
and innovations to control costs need to 
be developed while maintaining, or even 
improving, quality of care. The question 
is not whether this needs to happen, but 
how it should be achieved. WE CARE 
hopes to provide a forum for all involved 
stakeholders and make some important 
first steps in drafting a European R&D 
roadmap for 2035.
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On 1 July 2013 Croatia became the 28th Member State of 
the European Union, after over three decades of political 
and economic transformation. In the years before accession, 
Croatia implemented a number of important reforms in the 
health sector, including changes in payment mechanisms, 
pharmaceutical pricing and reimbursement as well as health 
care provision (emergency care reform). The most important 
one was the 2008 financial reform to address long-standing 
problems of hospital deficits.
However, continued reform effort are necessary, especially 
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economy, has put it under increased budgetary scrutiny. 
Recently, the European Commission urged Croatia to 
strengthen its cost-effectiveness, especially in the hospital 
sector, which still is fraught with inefficiencies and remains a 
key source of debt in the system.
This mounting pressure may 
further spur the implementation 
of the Government's 2012-2020 
National Health Care Strategy, 
which sets out reform priorities 
for the health care sector, such 
as coordination between various 
levels of care as well as improving 
quality and accessibility of care 
across regions.
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Summary: Until recently, multimorbidity has not received much 
attention from European policy-makers. This is changing now that it 
has become clear that the number of people with multimorbidity is 
rapidly increasing. The ICARE4EU project will help to improve, analyse 
and disseminate innovative patient-centred multidisciplinary care 
programmes or practices for people with multiple chronic conditions 
in Europe. Early project results show that although policy-makers 
are increasingly aware of the challenge of multimorbidity, national 
policies and strategies focusing on these patients have not yet been 
developed. Nevertheless, various types of multimorbidity programmes 
or practices have been implemented in all four countries under study.
Keywords: Multiple Chronic Conditions, Multimorbidity, Integrated Care Practices, 
Finland, Germany, Italy, The Netherlands, ICARE4EU
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aims to support the European 
Innovation Partnership on Active and 
Healthy Ageing and is co-funded by 
the Health Programme 2008 – 2013 
of the European Union. More 
information on the project and its 
partners can be found at:  
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Multimorbidity – the challenge for 
care delivery in Europe
Currently, an estimated 50 million 
(mostly older) people in the European 
Union (EU) live with multiple chronic 
diseases. 1  This deeply impacts on their 
quality of life, not only physically, but 
also mentally and socially. Until recently, 
multimorbidity – the occurrence of 
more than one chronic disease within 
an individual – has not received much 
attention from European policy-makers. 
This is changing, now that it has become 
clear that the number of people with 
multimorbidity is rapidly increasing. 
Indeed, the European Commission started 
a European Innovation Partnership on 
Active and Healthy Ageing in 2012, in 
which care integration and multimorbidity 
are explicitly addressed, while the World 
Health Organization recently launched 
a roadmap on a framework for action 
towards coordinated/integrated health 
services delivery.
The ICARE4EU (Innovating care 
for people with multiple chronic 
conditions in Europe) project  2  is an 
initiative co-funded by the EU’s Health 
Programme 2008 – 2013, which will 
help improve, analyse and disseminate 
innovative patient-centred multi-
disciplinary care programmes for people 
with multiple chronic conditions. In a 
previous article published in the 2013 
Eurohealth Gastein edition, 1  we discussed 
the multifactorial challenges that chronic 
illness care places on European health 
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systems. The key question is how to 
respond to this increasing demand for 
comprehensive multimorbidity care. 
Integrated care models have been seen 
by many as a solution to overcome this 
question by taking a holistic approach 
while making efficient use of resources.
This article describes some early results 
from our project. 3   4   5   6  We first describe 
whether national policies exist for chronic 
illness care, and more specifically 
multimorbidity care, and/or integrated 
care in four countries: Finland, Germany, 
Italy and the Netherlands. Furthermore, we 
introduce some first results of our survey 
among country experts by providing some 
examples of innovative integrated care 
programmes for patients with multiple 
chronic conditions in these four countries.
‘‘ lack of national policiesThe policy response to multimorbidityWhile policy-makers across Finland, Germany, Italy and the Netherlands are aware of the challenge of chronic 
diseases and multimorbidity, national 
policies specifically focusing on patients 
with multimorbidity have not yet been 
developed. Italy is the only country, 
where regional policies on multimorbidity 
management have been formulated (e.g. 
by the Chronic Related Group, and by 
the Expanded Chronic Care Model). 7   8   9  
In Germany, Italy and the Netherlands 
disease specific policies focusing 
on chronic diseases exist; however, 
these may not meet the special needs 
of multimorbidity patients. All four 
countries have developed policies aiming 
at better integration of care. While these 
do not explicitly target patients with 
multimorbidity, they often contribute to 
improved care for these patients as well.
Care practices addressing 
multimorbidity
Despite the lack of national policies 
specifically addressing multimorbidity, 
care practices focusing on multimorbidity 
care or management have been developed 
and implemented within the four countries. 
Overall 25 care practices or programmes* 
have been identified in the study so far. 
In Box 1 we provide two examples from 
each country in the study so far. Most 
are limited to the local or regional level, 
focusing on daily patient care. Regarding 
the multimorbidity orientation, several 
programmes in Finland, Germany and 
the Netherlands focus on multimorbidity 
in general. Other programmes are aimed 
at a specific diagnosis with a variety of 
possible co-morbidities or at a combination 
of specific chronic diseases.
The programmes display similarities 
with regard to process and quality 
related objectives, such as improved care 
coordination, increasing multidisciplinary 
collaboration and the promotion of 
evidence-based practice. In Germany, Italy 
and the Netherlands programme objectives 
were similar and focused on utilisation and 
costs, prevention/reduction of over-use of 
services and reduction of acute care visits. 
Most programmes address patients and/
or medical care providers as target groups. 
The main care providers involved in the 
programmes across all four countries 
are general practitioners (GPs) and 
medical specialists. Overall, the number 
and disciplines of medical specialists 
participating in the programmes vary 
greatly. In Finland, multi-professional 
development groups have been established 
to enhance integration and collaboration 
at a practical level. Most programmes 
involve hospitals and primary care 
practices. Overall, the programmes vary 
according to the level of integration of 
care, especially with respect to the number 
of medical specialists and health care 
professionals involved.
So far, the impressions of country experts 
and programme managers regarding 
programme outcomes are generally 
positive and some programmes have 
* We do not assume that all available (eligible) care practices 
or programmes in Finland, Italy, Germany and the Netherlands 
were identified.
already been evaluated. For instance, 
in Germany the programme Gesundes 
Kinzigtal had been evaluated on its 
processes, outcomes, long-term effects and 
cost-effectiveness. For the programmes 
that have not been evaluated thus far, 
evaluations are planned. For this purpose 
data on several indicators are collected 
regularly within the programmes 
(monitoring), so that quality information 
will become available for evaluation 
purposes.
‘‘ programme outcomes are generally positiveConclusion
While policy-makers across Finland, 
Germany, Italy and the Netherlands are 
aware of the challenge of multimorbidity, 
national policies specifically focusing on 
multimorbidity care or management have 
not been developed as yet. Nevertheless, 
the implementation of multimorbidity care 
practices is increasingly considered to be 
an important issue in these four countries. 
The current care practices or programmes 
addressing multimorbidity that we 
described in this article vary with regard 
to their target groups, care providers 
involved and especially their level of 
collaboration and integration. There is 
great value in making an inventory of such 
integrated care programmes addressing 
multimorbidity for all European countries 
and by doing so providing a rich dataset 
to better study their features, factors 
and conditions for successful outcomes 
and implementation, as well as their 
transferability to other European regions 
or contexts (e.g. patient groups, health care 
systems). The next step in the ICARE4EU 
project aims to do so by identifying 
good practices, based on survey data 
from 31 European countries and related 
to four main perspectives, namely their 
patient centredness, the use of e-health 
technology, their ways of financing 
and management and professional 
integration issues.
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Box 1:  Characteristics of programmes addressing multimorbidity in four countries
Programme Main objectives Target group








programme of POTKU 
(see above) in 
Pirkanmaa area.
Process
e.g. Improving care coordination, improving 





e.g. Preventing or reducing over-use of services, 
reducing emergency/acute care visits, reducing 
(public) costs
Access
Reducing inequalities in access to care and 
support services
Patient centredness
e.g. Identification of target group patients, 
improving patient involvement 
Patients with 
multimorbidity or 
patients who use a lot 
of services from many 
organisations or 
clinics.
In particular patients 
whose needs are not 
met by the services, 
who need proactive 
care planning or who 
need long-term care.










The programme has 
supported integration 
of care services, 
collaboration between 
care providers, 




involvement of informal 




between public health 
care and patient 
associations and 
patients are now 
included in the 
development of care.
Finland 
Chronic Care Model for 
Patients  with Multiple 
Diseases in Primary 
Care.
Process
e.g. Improving professional knowledge on 
multimorbidity, improving care coordination, 
increasing multi-disciplinary collaboration
Patient outcomes
e.g. Improving early detection of additional/
comorbid diseases, decreasing/delaying 
complications, decreasing mortality
Utilisation and cost
e.g. Preventing or reducing misuse of services, 
reducing hospital admissions, reducing (public) 
costs
Access
Reducing inequalities in access to care and 
support services, improving accessibility of 
services
Patient centredness
Identification of target group patients, improving 
patient involvement
Patients with multiple 









Primary care practices, 
health centres, patient 
organisations.











The programme has 
promoted integration 
of care services, 
collaboration between 
care providers, 




The care model is a 
useful tool for staff. 
From one portal the 
professionals can find 
everything they need to 
follow up with a patient 
with chronic diseases. 
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Programme Main objectives Target group




Qualität und Effizienz 
eG Nürnberg
Health network quality 
and efficiency eG in 
Nürnberg, the federal 
state of Bavaria
Quality of care
Improving integration of different organisations, 
increasing multi-disciplinary collaboration
Patient outcomes
Improving early detection of additional/
co-morbid diseases
Utilisation and cost





general, medical care 
providers, non-medical 
care providers and 
management.
General hospitals, 















coordination of care, 
improved cooperation 
between medical and 
non-medical care, 
staff and patient 
satisfaction, better 
patient involvement, 
changes in utilisation 
of resources, cost 
savings and it is 
transferable.
The objectives set in 
the programme were 
said to be completely 
reached.
Germany 
Gesundes Kinzigtal in 
Haslach in the federal 
state of Baden 
Württemberg
Quality of care
e.g. Promoting evidence-based medicine, 
improving professional knowledge on multi-
morbidity, increasing multi-disciplinary 
collaboration 
Patient outcomes
Improving early detection of additional/
co-morbid diseases, decreasing complications, 
morbidity, mortality
Utilisation and cost
Reducing hospital admissions, (public) costs
Improving patient centredness
e.g. patient involvement.
The programme refers 
to patients with 
multi-morbidity in 
general, medical care 
providers, non-medical 
care providers and the 
population.
General hospitals, 





pharmacy, insurer and 
management company. 
The programme 
involves several care 










of services, the 
collaboration of care 
providers and cost 
effectiveness. 
The objectives of the 
programme were said 








Utilisation and cost 
Preventing misuse of services 
Improving patient centredness 
Improving patient/informal carers involvement
Patients, informal 
carers and medical 
care providers. The 
programme specifically 
addresses people with 
physical disabilities 
(e.g. neuromuscular 
diseases, and chronic 
respiratory failure 
as comorbidity.
University and general 
hospitals, patient 
organisations. Care 
providers involved in 





Results seem to 
suggest mainly 
improved integration/
collaboration of care 
services/providers, 





The programme seems 
also to be transferable.
The results also 
suggest that the 




tranquility for patients 
and their caregivers.
Box 1:  Characteristics of programmes addressing multimorbidity in four countries (continued)
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Programme Main objectives Target group




REgioNs of Europe 
WorkINgtoGether for 
HEALTH *
* Multicentre Project 
involving the following 
European countries: 
Italy, Denmark (Lead 
partner),Norway 
Finland, Sweden Spain, 






Utilisation and cost 
Preventing over-use/misuse of services
Improving access 
Reducing inequalities and Improving accessibility 
in/to care and support services
Improving patient centredness 
Improving patient/ informal carers involvement 
Patients, informal 
carers and medical 
care providers. The 
programme generally 
addresses people with 
chronic diseases 
(e.g. heart failure, 
COPD, diabetes) aged 
18+ years, and more 
specifically frail elderly 
people aged 65+.
University and general 









institutes, regions and 
external providers.
Care providers involved 









Results show mainly 
integration/










of e-health tools and 
cost savings/
effectiveness. 
The programme is also 
transferable.
The Netherlands 
Guided Care Model – 
A disease seldom 
stands alone. 
Process
e.g. Improving professional knowledge, 
improving care coordination, increasing 
multi-disciplinary collaboration
Patient outcomes
Early detection of comorbidities, improving 
functional status, decreasing complications 
Utilisation and cost





Identification of target group, improving patient 
involvement, involvement of informal carers.
Patients aged 65 or 
older suffering from 
more than one disease 
or problem (physical, 
social, psychological, 
functional). 
Within this target 
group the following 
subgroups are 
specifically addressed:  
frail elderly, low health 
literacy, low income 
groups and people 
from deprived areas.
Involvement of primary 
care practices, health 
centres and centres of 
expertise in long-term 
care.
The Guided Care Model 
is an appropriate 
method for general 
practices. It enables 
care providers to 
manage the care for 
multimorbidity patients 
in a different way. 
Patients are positive 
about the increase in 
attention towards their 
personal health goals 
and the active support 
they feel they are 
receiving in reaching 
these goals.
The Netherlands 
INCA – the Integrated 
Care programme
Process
e.g. Improving integration of different units, 
increasing multi-disciplinary collaboration
Patient outcomes
e.g. Early detection of comorbidities, decreasing 
morbidity
Utilisation and cost
Preventing over- and misuse of services, 
reducing hospital admissions, reducing (public) 
costs
Access
Reducing inequalities in access to care and 
support services
Patient centredness
Identification of target group, improving patient 
involvement
Patients suffering from 
diabetes, COPD and/or 
vascular risk 
management. 
Within this target 
group no specific 
subgroups are 
specifically addressed. 
Patients aged 18 years 
or older.





sectors are involved 
according to patient 
needs.
Research institute
The evaluation showed 
that the INCA approach 
helps to realise the 
shift from disease 
orientation to patient 
orientation. The 
harmonisation across 
health care standards/ 
disease management 
programmes (DMPs) 
provides a base for a 
more individualised 
(tailored) approach. 
The modular approach 




Box 1:  Characteristics of programmes addressing multimorbidity in four countries (continued)
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The rising burden of chronic disease, and the number of people 
with complex care needs in particular, require the development 
of delivery systems that bring together a range of professionals 
and skills from both the cure (health-care) and care (long-
term and social-care) sectors. Failure to better integrate or 
coordinate services along the care continuum may result in 
suboptimal outcomes.
This Policy Summary analyses published reviews on the 
economic impacts of integrated care approaches. Given the 
wide range of definitions and interpretations of the concept, 
it proposes a working definition that builds on the goal of 
integrated care and which considers initiatives seeking to 
improve outcomes for those with (complex) chronic health 
problems and needs by overcoming issues of fragmentation 
through linkage or coordination of services of different 
providers along the continuum of care. The review covers three 
economic outcomes: utilisation, cost-effectiveness and cost or 
expenditure and also looks at data on core health outcomes 




What is the 







Available evidence of integrated care programmes points to 
a positive impact on the quality of patient care and improved 
health or patient satisfaction outcomes. However, uncertainty 
remains about the relative effectiveness of different system-
level approaches on care coordination and outcomes, with 
particular scarcity of robust 
evidence on the economic 
impacts of integrated care 
approaches. In addition, it 
is important to come to an 
understanding as to whether 
integrated care should be 
considered an intervention 
or whether it should be 
interpreted, and evaluated, as 
a complex strategy to innovate 
and implement long-lasting 
change in the way services 
in the health and social-care sectors 
are being delivered and that involve multiple changes at 
multiple levels.
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Summary: Personalised medicine is one of the most innovative areas 
in the future of health research. At present, its full potential cannot be 
developed due to fragmented activities, insufficient communication, 
and lack of generic solutions in the different areas of personalised 
medicine; moreover, implementation is a major challenge. The EU-
funded Coordination & Support Action PerMed was initiated to step 
up coordination efforts between key European stakeholders, to 
allow synergies and avoid duplication or competition, and to provide 
recommendations to foster the implementation of personalised 
medicine in transnational research and health systems.
Keywords: Personalised Medicine, Strategic Research and Innovation Agenda (SRIA), 
Europe, PerMed
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Personalised Medicine: present 
and future
Health care as we know it is radically 
changing to give way to increasingly 
more personalised health interventions for 
citizens and offering more personalised 
therapies and treatments for patients. 
Essentially, Personalised Medicine (PM) is 
an innovative method of treating citizens 
and patients that utilises research, data and 
up-to-the-minute technology to provide 
better diagnostics and follow-up for 
citizens than is currently the case. Among 
others, it uses genomic information to 
discern whether a particular intervention 
will work for a particular patient and 
assists clinicians in deciding which 
treatment will be the most effective. It can 
also have a huge impact in a preventative 
sense (see Box 1).
However, we are only at the beginning of 
the road and many challenges have to be 
overcome in order to benefit from PM’s 
full potential. The era of ‘one size fits all’ 
in medicine is slowly coming to an end. 
Personalised treatment options are being 
developed for an array of conditions and 
some have already entered the market. 
Treatments for cancer are leading the 
field, but they are followed closely by 
treatments in cardiovascular, pulmonary, 
infectious and psychiatric conditions, 
among others. Personalised therapies 
aim to provide “the right treatment to the 
right patient at the right time”, with early 
diagnosis, increasing efficacy, decrease in 
adverse drug reactions, and cost-effective 
treatments that may result in cost savings, 
quality of life improvement, and reduction 
of general morbidity in the population.




Eurohealth incorporating Euro Observer — Vol.20 | No.3 | 2014
42
Despite being a concept already applied 
by Hippocrates more than two thousand 
years ago in Ancient Greece, the 
advances in the so-called “omic” sciences 
(genomics, transcriptomics, proteomics, 
metabolomics, etc.) and in Information 
and Communication Technologies (ICT) 
have led to enormous advances in the 
field of PM in the past two decades. 
Greater understanding of the molecular 
basis of disease and all the factors, such 
as environmental factors influencing 
disease onset, progression and response 
to treatment, together with the staggering 
fall in the costs of gene or genome 
sequencing and genotyping, plus faster 
results availability, have resulted in the 
market entry of over twenty personalised 
therapeutics; such as Herceptin, the first 
personalised treatment approved sixteen 
years ago for HER2+ metastatic breast 
cancer. The development of many more 
is underway. However, the scope and 
approach of PM is not limited to the 
treatment of diseases only; it is much 
broader and inclusive, also covering 
areas such as lifestyle advice, prevention, 
environmental interventions and even the 
structure and organisation of hospitals and 
health systems. Furthermore, the increased 
interest from physicians, decision 
makers, regulators and the general public 
in PM has contributed to its increased 
application. Figure 1 shows the number of 
publications on PM in the past 40 years, 
and their exponential rise particularly in 
the last ten years. Notwithstanding the 
great interest, we are still only at the start.
Although the US may have been leading 
the field in the past, Europe is showing 
a clear commitment to PM. Reports 
have been published by the European 
Commission (EC) supporting the 
mission of personalisation of health and 
many politicians and decision makers 
have expressed their support. For 
example, in the UK,  2  Germany  3  and 
France,  4  the national governments have 
made a strong commitment – implicitly 
or explicitly – to genomic medicine and 
the application of PM, mostly in cancer 
research and treatment. Furthermore, the 
EC’s new Horizon2020 research grants 
programme – initiated in January 2014 – 
will promote research in all aspects of 
targeted therapies, including ICT to assist 
decision-making in PM. As the Director 
General of DG Health and Consumers 
(DG SANCO), Paola Testori Coggi, puts 
it “it is essential for Europe to build on 
our strengths to develop innovations to 
promote growth and benefit European 
citizens. Genomics has the potential to 
be a key sector contributing to this in 
the future … Advances in PM can bring 
business development and economic 
growth to Europe in addition to improved 
prevention, treatment and care to 
European citizens.”  5  These objectives 
form the basis of CSA PerMed, otherwise 
known as the Coordination & Support 
Action (CSA) Personalised Medicine 2020 
and beyond (see Box 2).
‘‘ still only at the startThe development of PM in Europe represents an important paradigm shift for all health care systems and poses major challenges – both for the present and the future. These challenges need to be overcome to meet the objectives 
of Europe 2020, the Digital Agenda, the 
Innovation Union and Horizon 2020  6  
by bringing together: research for health, 
innovation for health and health equity, 
and significant contributions to global 
research and innovation systems. 
A general change in mind-set in health 
care delivery is also needed.
Realising potential benefits
Why should we strive towards the 
personalisation of health care and 
promote the four Ps in health (predictive 
and preventive, personalised and 
participatory)?
There are potential benefits from applying 
evidence-based personalised treatments, 
including:  7 
–  improvement of informed medical 
decisions
–  shift from reaction to disease towards 
prevention and prediction of disease
–  targeted therapies with higher 
probability of success
Box 1: Definition of Personalised 
Medicine
“ Personalised medicine refers to 
a medical model using molecular 
profiling for tailoring the right 
therapeutic strategy for the right 
person at the right time, and/or 
to determine the predisposition to 
disease and/or to deliver timely and 
targeted prevention.” 
Source: Ref. 1 
Figure 1:  Number of publications per year on Personalised Medicine, 1971 – 2014 
Source: PubMed, last search on 1 June 2014 with search terms “personalized medicine”- or “personalised medicine”  
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–  risk reduction with fewer adverse 
reactions to medicines
–  timely/early disease interventions
–  cost-efficient treatment solutions and 
general health care cost containment.
For health systems as a whole, potential 
benefits include early systematic dialogue 
between the relevant key stakeholders, 
citizen-centred health care systems, 
encouragement of patients to be more 
active in their health management and feel 
greater ownership in the responsibility of 
their health, support quality of life, health 
and wellness, yield a maximum return on 
health care investment and adjustment to 
the needs of sub-sectors of the population, 
among others.
Nevertheless, a great deal still needs to 
be done to reach these benefits across 
the entire health care spectrum, and 
not restrict them to a limited number of 
conditions. The challenges have been 
widely discussed and described in a large 
number of reports and publications (see 
next paragraph for examples).
The way forward
PerMed has identified and evaluated the 
information already available as well as 
the strategy documents published by key 
stakeholders, including reports, guidelines 
and roadmaps on PM. A gaps and needs 
analysis was performed on 18 relevant 
reports – from the EC,  1  the European 
Science Foundation (ESF),  7  the European 
Alliance for Personalised Medicine 
(EAPM),  8  the Public Health Genomics 
European Network (PHGEN),  9  the 
European Medicines Agency (EMA),  10  the 
iNNOVAHEALTH Conference under the 
Cyprus EU Presidency  11  and the European 
Hospital and Healthcare Federation 
(HOPE)  12  among others – and over 35 
interviews were carried out with relevant 
stakeholders.
‘‘ change in mind-set in health care deliveryRegardless of their authors, interests and target group, these reports and interviews 
reach similar conclusions on the aspects 
that need to be tackled. These are:
1.  Targeted research in molecular 
mechanisms and ICT
Targeted research to better understand 
the molecular mechanisms of disease 
and all implicated factors, as well 
as the identification and validation 
of biomarkers, is essential for the 
development of further personalised 
therapeutics. Multidisciplinary research 
teams, joining the knowledge from a 
variety of sciences, together with cross-
disciplinary and cross-border collaboration 
in research and in drug development 
are essential parts of the R&D process 
of PM. Further developments in data 
collection, storage, management, sharing, 
mining, processing and analysis are also 
imperative. ICTs have not been exploited 
to their full potential and will surely 
push forward the individualisation of 
medicine in all areas (research, translation, 
diagnosis, treatment decision-making, 
follow-up, etc.).
2.  Adaptive business models, 
translational pathways and systematic 
early dialogue
The current business model for 
pharmaceutical companies is no longer 
valid once we move away from the “one 
size fits all” drugs. Pre-competitive 
collaboration between companies 
(pharmaceutical companies and medical 
device manufacturers, for example), the 
increase in public-private partnerships 
and a more flexible and adaptive business 
model is needed for the development and 
translation into health care of personalised 
technologies. Furthermore, systematic 
early dialogue with regulators and patients 
at an early phase of development would 
lead to more efficient drug development 
and translation processes. Clinical trial 
designs need to change: Phase III studies 
with thousands of patients are not possible 
and adaptive designs with smaller numbers 
of patients are needed, like the ones 
already being conducted in cancer that 
permit the application of personalised 
treatment options under one protocol. 
New dynamic and sustainable pathways 
that lead to timely and effective translation 
of innovative technologies into health 
policies and health care are needed, always 
ensuring high quality, safe and efficient 
treatments entering the market.
3.  Make regulation simple, coherent 
and predictable
In addition, the regulations that are in 
place nowadays do not consider the 
specificities of personalised interventions, 
including therapeutics. Many of the 
ones that affect PM are being revised, 
but remain far from ideal. Especially 
in Europe – considering the inherited 
heterogeneity of our Member States – 
simplified, harmonised, coherent (across 
directives and regulations) and predictable 
regulatory procedures are welcomed. 
Some positive steps forward are the new 
medical devices directive regulating (for 
the first time in Europe) in-vitro and 
companion diagnostics, and the proposed 
adaptive licensing model from EMA. 10  
In order to expand its leadership role, it is 
Box 2: The PerMed consortium
CSA PerMed is a consortium – created 
by decision makers in Europe, including 
more than ten ministries and funding 
bodies – which aims to prepare 
Europe to be a global leader in the 
implementation of PM. It differs from 
other consortia and working groups 
due to the partners involved and its 
aim to carry out focussed discussions 
on concrete research actions, rather 
than prolonging on-going broad 
discussions and recommendations 
(see www.permed2020.eu). Moreover, 
transparency, openness, collaboration 
and the avoidance of duplication lie at 
the core of the CSA PerMed approach. 
The consortium’s unique features create 
the potential to develop a strategic 
research and innovation agenda for 
Europe (SRIA) and be the starting point 
for a European Innovation Partnership 
(EIP) in PM acting across the entire 
research and innovation chain, bringing 
together key actors at European, 
national and regional level.
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PerMed’s view that Europe could engage 
in international efforts to harmonise 
regulatory aspects.
4.  Driving health care systems towards 
preventive care
When it comes to health care systems, a 
general change in mind-set in health care 
delivery and provision is needed. From 
a coordinated reimbursement process for 
drugs and diagnostics, new financing 
strategies, new structures and models at 
the provider level, updated health care 
professional training and a change in 
attitudes, a shift towards preventive care, 
towards new cost assumption models, 
changes in patient behaviour and an 
increased interest and literacy from 
citizens in general are needed. The social 
consequences of the implementation 
of PM have not been fully studied, and 
there are many ethical challenges that 
lay ahead, which is why the principles of 
“Ethical, Legal and Social Implications” 
(ELSI) are essential and need to be further 
explored by research and applied by all 
stakeholders.
Conclusion
Even though PM may be one of the 
most innovative areas in the future of 
health research, the full potential for 
patients, citizens and the economy in 
Europe currently cannot be realised due 
to the inherited fragmentation between 
European Member States, inadequate 
communication and lack of common 
vision on the solutions that are needed. 
Appropriate governance levels are 
required to solve these challenges.
PerMed aims to provide concrete 
recommendations and to take a big step 
forward towards PM for all, without 
forgetting that the ultimate goal is to 
bring the right health intervention to the 
right patient at the right time, to avoid as 
many adverse reactions as possible during 
treatment, to make it affordable for health 
care systems and to ensure equality in 
access to personalised innovations. As 
long as the interests of citizens drive work 
towards this common mission, Europe can 
become a leader in PM, with the potential 
to also create business and economic 
growth and, most importantly, give 
patients access to safe, highly efficient and 
targeted treatments in a timely and cost-
efficient manner.
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Summary: Strengthening primary care is central to the ongoing health 
care reform in Austria, where patients can still enter the system at any 
point. Limiting this high degree of freedom is crucial for the reform to 
be effective. However, as it is much less popular to reduce choice than 
to extend it, the challenge health policy-makers are currently facing 
is considerable. Rebalancing care coordination, choice and voice in 
a multi-faceted approach might be a solution.
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Introduction
With the rise of chronic diseases, change 
towards providing evidence-based, 
continuous care across sectors has become 
a paramount goal for health care systems, 
including a strengthened primary care 
system to improve care coordination. 
However, this goal seems somewhat 
antithetic to the idea of a patient’s freedom 
to choose any provider. Whereas in many 
countries, people are required to register 
with a general practitioner (GP) and 
to use him or her as the primary entry 
point, patients in health care systems 
like in Austria or Germany are used to 
having access to nearly any provider at 
any time. However, this comes at the 
cost of patients entering the care process 
at arbitrary points and impairs efforts 
to ensure coordination and continuity 
of care. Reducing this freedom for the 
“greater good” might be met with a lot of 
resistance by insurees as well as provider 
representatives and therefore might come 
at a high cost for health policy-makers.
Austria’s health care system has been 
criticised for its fragmented, hospital-
focused way of providing care for its 
population. The ongoing health care 
reform in Austria envisages a change 
towards strengthening primary health care 
(PHC), an area in which the country is 
traditionally weak, and a first concept was 
approved on 30 June 2014. Thus, decision 
makers find themselves in exactly the 
position of promoting new ways of service 
delivery that have the innate feature of 
reducing freedom of choice. After a phase 
of tiptoeing around the subject, they need 
to get more specific on the details as 
the design for implementation has to be 
drawn up.
The case of Austria
When, in 2012, policy-makers decided to 
implement a fundamental reform, they 
wanted to amend some of the traditional 
challenges with the Austrian health care 
system. In the outpatient sector, the 
prevalent form of care delivery is the 
➤  #EHFG2014 Forum	3: 
Balancing care coordination 
and patient choice
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single practice, with the physician as the 
only medical professional. Out-of-hours 
care is rarely provided in the GP sector, 
making the hospital a convenient entry 
point. There is no real PHC system in the 
sense outlined by Starfield et al. 1  or the 
European Commission’s Expert Panel on 
Investing in Health  2  in terms of continuity 
or care coordination. The patient is free to 
enter the health system at a GP, a self-
employed specialist, or a hospital. If he/she 
never does go to the doctor, in principle no 
one cares. Due to fragmented financing of 
acute care between social health insurance 
(SHI) and all levels of government, 
coordination of care efforts is usually poor. 
The somewhat paradoxical consequences 
are i) rather satisfied patients due to a 
menu of care options and few restrictions; 
ii) health care expenditures among the 
top five in Europe; and iii) only average 
outcomes for chronic diseases.
The ongoing reform emphasises the 
need for more preventive care, a true 
PHC system and refocusing care and 
corresponding funds by payers sharing 
the responsibility and funding rather than 
butting heads. However, there is still no 
clear position on how to cope with one of 
the less popular elements of the reform, the 
need to reduce freedom of choice in favour 
of more care coordination and continuity.
The costs and benefits of PHC
The case for PHC has been well made in 
the literature by Starfield  1  and subsequent 
authors. 3  Strong PHC means a lower 
threshold for comprehensive care for the 
population. This results in more timely 
interventions, better coordination and 
continuity of care for chronic conditions 
and better conditions for preventive efforts. 
These features of PHC have numerous 
beneficial effects: hospitalisations for 
many chronic conditions can be reduced; 
population health can be improved on 
several dimensions; while socioeconomic 
inequality is reduced. When it comes to 
the downsides of such a system, probably 
two things are worth mentioning. 
Countries with a stronger PHC system 
were found to have higher health care 
expenditures, albeit lower growth rates. 3  
Moreover, an innate feature of PHC is 
that people stay on the list of a GP and 
by accepting him/her as the primary 
entry point to the health system they are 
effectively constraining their freedom.
‘‘ satisfied patients due to a menu of care optionsWhen it comes to Austria, these effects can be perceived with one notable 
exception. Health care costs are among 
the highest in Europe, and introducing 
primary care in this case might actually 
drive down costs in the long run due to 
better allocative efficiency of spending, 
after a phase of investing in better 
primary care.
The costs and benefits of provider 
choice
Choice can be exerted on different levels. 
The first level is choice of insurer and 
choice of insurance plan (with its different 
subcategories), which is normally only 
potentially possible in insurance-based 
countries, with the exception of moving 
elsewhere in regionalised Beveridge 
systems. The second is choice of providers 
on different sub-levels, i.e. choosing a GP, 
a specialist, an integrated care programme, 
a treatment centre or a hospital for 
ambulatory or inpatient care. The third 
is choice with respect to treatment. 
However, we will first concentrate on 
provider choice as this is at stake when 
strengthening primary care.
A lot has been written about the costs 
and benefits of provider choice in the 
context of health care systems that 
consider expanding it,  4   5  but less so for 
health care systems that probably need 
to reduce it in favour of patient guidance 
and how this can be achieved. While the 
freedom to choose providers is expected 
to increase their quality and efficiency 
through competition, these effects also 
hinge on some form of overcapacity and 
the availability of information as well as 
the ability of patients to process it. The 
latter requirement has sometimes led to 
the perception of choice as inequitable, 
as it favours the better educated and well 
off. Then again, not giving anyone the 
opportunity to make an informed choice 
is not in itself beneficial.
Other arguments invoked are increased 
transaction costs, as can be seen in the 
overall higher health care spending of 
most SHI countries, where the feature of 
provider choice is normally built-in. In 
the context at hand, probably the most 
important downside of choice is the danger 
of fragmenting care. On the other hand, 
being able to choose a provider might also 
improve satisfaction and provide a better 
provider-patient fit.
Eventually, people just seem to “want” 
to be able to choose. For health care 
systems that offer free choice of provider, 
this fact seems to be the biggest policy 
challenge when attempting to increase 
care coordination.
Challenges in Austria
From discrete choice experiments (DCE) 
we know that people value choice quite 
highly when they are used to it (see for 
example a DCE for Germany and the 
Netherlands  6 ). The reality test in the form 
of the Hausarztmodell in Germany or 
HMO/telemedicine-plans in Switzerland 
show that insurance companies have to 
compensate people for reduced choice 
with considerably reduced premiums and/
or user charges. In fact, when not using 
considerable financial incentives (or 
probably even then), such initiatives are 
met with little enthusiasm.
But the preference not to give up (some) 
choice is only part of the story. Setting 
up a PHC system that lives up to the 
name requires a whole lot more than just 
giving up the possibility of self-referral 
to a specialist. Many failed attempts to 
improve care coordination by restricting 
provider choice seem clumsy in hindsight. 
Just by offering some monetary incentive 
or introducing user charges does not make 
people go where policy-makers want, 
especially if the attempts are indecisive. 
If visiting my GP first* is so beneficial, 
* The point here also is that just visiting a GP as a formality 
prior to a specialist is not what strong primary health care 
is about.
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then why is it voluntary and people try 
to pay me for it? Problems here seem 
to arise at least from three aspects: the 
prerequisites for, the process of, and the 
means used in the reform.
‘‘ what forms of choice really matterWhen it comes to prerequisites, it was probably underestimated in many cases how demanding a PHC system is. Making GPs gatekeepers does not make them 
better trained or allow them to acquire 
knowledge instantly about procedures 
for which they have previously referred 
patients to a specialist. Neither will 
patients believe this is so, and even less 
so after having been told for decades 
that specialists provide better care. Self-
employed specialists depend on self-
referrers for income and have gotten used 
to being bothered with minor problems 
that are treated by GPs in other countries. 
In addition, outpatient departments in 
hospitals have expanded their capacities 
to receive many people who are simply 
unwilling to make an appointment 
outside, and while complaining about 
the encumbrance, hospital management 
remains reluctant to move services and 
funds to other providers. In other words, in 
countries like Germany, France or Austria, 
there is simply no tradition, no culture 
and no institution that would ready these 
countries for the quick introduction of 
true PHC.
The underestimation of these institutional 
factors also seems to be an explanation for 
the fact that the process of reform in these 
countries might not always have been up 
to the challenge. When France, in 1998, 
shyly introduced the option for insurees to 
enrol in a gatekeeping system connected 
to financial incentives, uptake was very 
poor. 7  In Germany, the Hausarztmodell 
is still contested by many and far from 
the success it was expected to be. 8  What 
is even more striking is the timeframe 
of these reforms. Institutional change 
can only be achieved over extended 
periods of time, but reforms often seem 
goal-oriented, trying to implement the 
state of the system envisaged rather than 
implementing the change needed to attain 
this state in the future.
The means to introduce more care 
coordination have also been quite simple 
despite the experience that changes 
to complex systems need a bundle of 
measures to balance out its adaptions. The 
answer has often been to simply introduce 
gatekeeping, some disease management 
programme (DMP) and/or user charges 
to discourage other forms of care use. 
In 2000, Austria introduced user charges 
for outpatient departments in hospitals 
(Ambulanzgebühr) as a singular measure, 
which was abolished the same year. In 
contrast to Austria or Germany, France 
found itself with the comfortable solution 
that it relies on in-cash benefits. In a 
second attempt to introduce a voluntary 
form of gatekeeping in 2004, the médecin 
traitant (a preferred provider system), 
reimbursement was severely cut for 
directly accessing specialists along with 
incentives for the common voluntary 
insurance schemes not to cover this form 
of user charge.
A more complex matter: provider 
choice and voice
While Hirschmann  9  started to draw our 
attention to the importance of voice and 
exit as a means to improve responsiveness 
more than forty years ago, the interaction 
of preferences in the population, different 
levels of choice and options to voice 
opinions is very complex. Nevertheless, 
the literature on the matter has begun to 
develop a far more differentiated look at 
what forms of choice really matter and 
what numerous ways there are to make 
oneself heard.
Many health care systems have tried 
to increase choice and/or voice and we 
can find a wide variety of combinations 
out there. 10  While maintaining the 
gatekeeping-function of the GP, the UK 
gradually expanded choice of GP as well 
as choice on higher levels of care, similar 
to the Scandinavian countries. So instead 
of choosing between all providers, choice 
can be exerted when entering a new level 
of care.
Traditionally, these countries also engaged 
in some form of public involvement and 
strengthened patients’ rights. The Danish, 
for example, conduct an annual patient 
survey and feed the information back 
to all levels of decision making. They 
also support patients with information 
on health related matters and quality of 
providers on www.sundhed.dk as well as 
through a system of patient counsellors. 
In England, the system’s struggle for 
patient empowerment produced the 
NHS constitution. NHS Choices (online) 
and NHS Direct (replaced by NHS 111 
since March 2014) provide information 
on a wide variety of topics including 
support to find the right provider and 
(unusually detailed) information on 
quality of providers. Local Involvement 
Networks are supposed to empower the 
public in matters of local health care, 
and the Care Quality Commission, 
while keeping a close eye on providers, 
also conducts numerous surveys that 
are expected to improve the system. In 
the Netherlands, with the quite unusual 
feature of gatekeeping in an insurance-
based country, there is a strong tradition 
of public involvement and laws that 
emphasise the right to information and 
strengthen the position of patients and 
their representatives under the umbrella of 
the Netherlands Patients and Consumers 
Federation (NPCF), apart from choice of 
insurance company. Strong patient rights 
to information and involvement in the care 
process have been enacted. Kiesbeter is 
a website with similar information to its 
Danish or English counterparts. Insurers 
and providers are required to involve the 
public in their decisions through counsels 
and/or surveys, and the NPCF is also 
represented on national boards.
Naturally, not all of these activities work 
perfectly and much can be improved. 
However, these examples show how health 
systems try to handle the delicate balance 
between choice and voice.
A new balance is needed
Whether Austria really offers that 
much choice in the first place has to 
be scrutinised. People have no choice 
concerning their insurer, nor can they 
choose between different insurance plans. 
When it comes to choosing a provider, 
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the field is wide open, but information on 
medical issues (like patient versions of 
guidelines), services or quality of service 
provided is widely lacking compared to 
what is offered in countries like England 
or the Netherlands.
An imminent challenge for health policy 
in Austria is to find a new balance between 
provider choice and the introduction of 
a functioning primary care system. As 
always in such complex matters, bundles 
of measures rather than singular measures 
seem appropriate, and internationally we 
can find a lot of role models.
Austria could change the “choose between 
all providers” maxim to a “choose 
between the right providers” maxim. 
Choice can still be exerted, but only 
on each level of care separately, as is 
common in other countries. In addition 
to this, people should be empowered to 
make informed choices in the first place, 
by making available patient guidelines, 
more information on providers and a 
telephone service. Decision makers also 
have to ensure the quality of primary care 
providers, so people can trust them with 
their health. They also have to actively 
communicate the benefits of primary 
care to the population rather than leaving 
the field to the preservers of the status 
quo. When provider choice is limited to 
some degree in a new system, it is also 
important to make sure that patients have 
a say in their treatment. This is still far 
too uncommon in the rather paternalistic 
medical tradition.
On a more general level, there are many 
other ways to gauge the preferences of 
people. While introducing primary care, 
Austria can improve public involvement in 
the decision making process. The position 
of patient representatives and self-help 
groups with respect to providers can be 
strengthened. Furthermore, surveys can be 
used on a more regular basis to ensure that 
information is fed back to providers and 
decision makers.
While we can learn a lot from other 
countries to rearrange the balance between 
choice of provider and care coordination, 
the political process poses an immense 
challenge. A lot remains to be done to 
ensure the success of the ongoing health 
care reform, but efforts should also be 
refocused. The health care system is not 
a machine, but a complex social system. 
Therefore, it seems to be necessary not 
only to implement the beneficial changes 
that are on the agenda. Before these seeds 
can take roots, the ground itself has to be 
more thoroughly prepared by measures 
that are aimed at changing institutional 
patterns.
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Introduction
More than two decades have passed since 
the break-up of the Soviet Union in 1991. 
This momentous event changed the 
political geography of Europe, with many 
countries that were once part of the Soviet 
bloc eventually entering the European 
Union (EU) in 2004 and 2007, including 
the three Baltic states (Estonia, Latvia and 
Lithuania). The situation has been different 
for the twelve former Soviet states that 
have remained outside the enlarged EU 
(Armenia, Azerbaijan, Belarus, Georgia, 
Kazakhstan, Kyrgyzstan, the Republic 
of Moldova, the Russian Federation, 
Tajikistan, Turkmenistan, Ukraine and 
Uzbekistan). Many of them are still 
beset with problems resulting from an 
unrealised reform agenda, as well as 
problematic socio-economic or political 
contexts. This article examines what has 
been happening in the health systems 
in these twelve former Soviet countries, 
summarising key elements of a newly 
published comparative analysis. 1 
Health trends
The collapse of the Soviet Union was 
followed by one of the most dramatic 
drops in life expectancy in peace time. 
Declines were particularly pronounced 
among men in the Russian Federation, 
with male life expectancy falling 
by 6.2 years between 1990 and 1994, to 
just 57.6 years. Although declines were 
less dramatic in other countries of the 
region, as a rule, life expectancy dropped 
in the first half of the 1990s, with only 
a slow recovery since then. Overall, 
the gap in life expectancy with western 
Europe has increased over the past two 
decades. Worryingly, people in the region 
can expect to die much earlier than their 
counterparts in western Europe, even 
in those countries with economies that 
are booming thanks to the extraction of 
natural resources (Azerbaijan, Kazakhstan 
and the Russian Federation).
The main causes of death contributing 
to this persisting gap in life expectancy 
are circulatory system disorders (most 
notably ischaemic heart disease) 
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and external causes such as injuries, 
violence and poisoning. In 2011, directly 
standardised all-cause mortality rates for 
under 65 years old per 100,000 population 
in the Commonwealth of Independent 
States (CIS) exceeded the EU average by 
a factor of three for males (801 and 269 
per 100,000 respectively), while mortality 
rates were more than two times higher 
for females (308 and 131 per 100,000 
respectively). Major risk factors include 
high alcohol consumption (in particular 
hazardous drinking of spirits and surrogate 
alcohols, i.e. substances including ethanol 
but not meant for consumption), high 
smoking prevalence, poor nutrition and 
poor access to effective health care. Other 
pertinent health problems include high 
(although decreasing) rates of tuberculosis 
and, in several countries, an increasing 
burden posed by HIV/AIDS.
‘‘ the gap in life expectancy with western Europe has increased
Organisation and governance
The organisation and governance of health 
systems in the region has also seen major 
upheavals in many countries, although 
some have been resistant to change. 
Several countries have experimented with 
the decentralisation of responsibilities, 
usually as a consequence of broader 
administrative reforms. Sometimes, 
this has exacerbated unclear divisions 
of responsibilities, leading to weak 
coordination and major inequities among 
regions. To varying degrees, parallel 
health systems from ministries or major 
state companies inherited from the 
Soviet period have persisted, resulting 
in duplication and fragmentation, 
undermining the effectiveness of the 
broader health system. Overall, the 
effective governance of health systems 
is undermined by a lack of quality data, 
lacking transparency and accountability, 
large informal sectors, the existence 
of informal payments, underdeveloped 
systems to ensure patient rights, lack of 
awareness of entitlements, fragmentation 
across different tiers of government, 
insufficient regulation of the emerging 
private sector, and a limited involvement 
by the public and of professional 
associations in health policy development. 
In all these respects, the post-Soviet 
countries are restricted in their ability to 
provide effective, timely and responsive 
care to those in need of it.
Health care provision
Two major foci of reforms in health care 
provision in the post-Soviet period were 
attempts to downsize hospital sectors 
and, correspondingly, strengthen primary 
health care. The collapse in government 
health funding in the early 1990s 
necessitated reductions in the oversized 
hospital sectors inherited from the Soviet 
period. However, closures were often 
confined to small rural facilities, while 
few hospitals in urban areas were affected 
and politically powerful tertiary care 
facilities have remained virtually immune. 
Most countries in the region still have a 
higher ratio of acute care hospital beds per 
capita than EU member states and there 
is also still a much longer average length 
of stay. However, the lack of investment 
in modern technology, or if it is present, 
of using it effectively, coupled with the 
low status of nurses and some other health 
workers, limits the scope to improve 
productivity.
Far too often, patients are admitted to 
hospitals for the wrong reasons. In some 
countries of the region, patients are up to 
ten times more likely to be hospitalised 
for hypertension than in OECD 
countries, a condition that rarely requires 
hospitalisation in western countries. 2  
Other examples of conditions that are 
commonly treated in hospitals rather than 
outpatient facilities include tuberculosis, 
diabetes and drug addiction. 3  Reasons for 
keeping patients in hospitals longer than 
necessary include weak gatekeeping in 
primary care, poor integration of care and 
perverse financial incentives for over-
hospitalisation. 4   5 
Strengthening primary health care was 
another key objective of health reforms 
in almost all former Soviet countries, 
often supported by international 
agencies. 6  Most commonly, however, 
the Soviet model of primary health care, 
delivered by doctors with only basic 
training and able to treat a limited range 
of conditions, has been retained and 
primary health care based on a model 
of comprehensive family medicine 
is confined to pilot sites. Exceptions 
are Kyrgyzstan and the Republic of 
Moldova. In general, progress in primary 
health care reforms has been slow. One 
challenge is that resource allocation 
still prioritises secondary and tertiary 
care. Weak gatekeeping and referral 
systems, poor integration of care, and 
low public confidence in primary health 
care are other problems. Primary health 
care facilities in rural areas also find it 
difficult to attract staff and to secure 
other resources.
Despite attempts to improve it, quality 
of care remains a concern at all levels 
of care. The reasons for poor quality are 
many but include a lack of investment 
in facilities and technologies (as noted 
above), problems with the pharmaceutical 
supply chain, inadequate training of 
health workers, underdeveloped patient 
rights, absence of systems for quality 
improvement, the paucity of locally 
generated evidence, limited access to the 
international literature, widespread out-of-
pocket payments (encouraging expensive 
and unnecessary treatments), poor 
integration of different levels of care, and 
the persistence of incentives to hospitalise 
patients. 3   7   8  Surveys have shown 
that only a very small percentage (less 
than 10% in many post-Soviet countries) 
of those with high blood pressure take 
necessary medications regularly, 9  and 
treatment rates for those with elevated 
levels of cholesterol are even lower. 2 
Health financing
Some of the most profound changes in 
the post-Soviet period have occurred in 
the area of health financing. Following 
the collapse of government funding for 
health in the early 1990s, private out-of-
pocket payments have become common, 
both in the form of official co-payments 
and in the form of informal, under-the-
counter payments. In 2012, the proportion 
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of government spending in total health 
expenditure was less than 50% in five 
(Georgia, Azerbaijan, Tajikistan, Armenia 
and Republic of Moldova) of the twelve 
post-Soviet countries considered here. 
This poses a serious challenge to equity, 
as out-of-pocket payments reduce financial 
protection, equity in finance, equity in 
utilisation and access to services. 10 
‘‘ quality of care remains a concernGovernments have responded to this new reality by defining benefits packages with limited scope and shallow coverage. Most often, outpatient pharmaceuticals are 
excluded and so they now form a major 
component of private health expenditure. 
A secondary analysis of household surveys 
in eleven eastern and central European 
countries found that expenditure on 
drugs accounted for as much as 75% 
of household spending on health in the 
Republic of Moldova and more than 50% 
in Kyrgyzstan, Tajikistan and Azerbaijan. 2 
Some countries (most notably Kyrgyzstan, 
the Republic of Moldova, and the Russian 
Federation) have instituted mandatory 
health insurance systems. These reforms 
have sometimes been the driving force 
for comprehensive reforms of health 
financing, designed to improve equity 
and efficiency. 11  Many countries are also 
adopting payment mechanisms used in 
western Europe, with case-based payment 
mechanisms for hospitals, while primary 
care is now predominantly financed on 
a capitation basis.
Conclusion
Health systems in the former Soviet 
countries still have a long way to go to 
reach the standards found in western 
Europe. Most fundamentally, they perform 
poorly in improving population health. 
This applies to both non-communicable 
and communicable diseases, as well as 
curative care and inter-sectoral public 
health actions. For more progress to be 
made, it will be essential to afford health 
a higher priority on government agendas 
and push the reform agenda forward.
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Introduction
European health care systems all face 
the same challenge: assuring high-
quality health care while at the same time 
containing costs. Quality of care is one 
of the most frequently mentioned goals 
of health care systems and ranks high 
on the European as well as on the global 
health policy agenda. 1  The introduction 
of measures aiming to achieve more cost 
efficiency, e.g. hospital payment through 
Diagnosis Related Groups (DRGs), to 
many, may appear diametrical to this 
quality objective. Against this background, 
the development of approaches assuring 
quality of care is of crucial importance 
in Germany and may hold lessons for 
other countries looking to improve 
hospital quality.
Quality assurance measures have already 
been legally required in Germany since 
the Health Care Reform Act of 1989. Yet, 
the German health system’s performance 
only ranked 25th in the WHO Health 
Report 2000, which initiated both 
extensive discussions and an increased 
focus on improving quality of care. 
Both the Statutory Health Insurance 
(SHI) Reform Act of 2000 and the SHI 
Modernisation Act of 2004 introduced 
new requirements for internal and 
external quality control in service 
provision, encompassing structural, 
process- and outcome-related dimensions 
of performance. The 2013 coalition 
agreement includes further proposals 
for various measures with a focus on the 
promotion of quality. Some of these have 
entered into effect with the Act to Further 
Develop the Financial Structures and 
Quality in SHI, which passed parliament 
on 5 June 2014.
This article aims to provide an overview 
of quality assurance measures in place in 
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the German health system. To this end, we 
first describe the regulatory environment 
for quality assurance. Second, we explore 
the approaches to internal and external 
quality control in German hospitals. 
Third, we examine to what extent and how 
quality is publicly reported. Lastly, we 
discuss what benchmarking approaches 
are in use before finishing with new 
initiatives and conclusions.
‘‘ explicit focus on quality assuranceRegulatory environment for quality assuranceThe Federal Joint Committee 
(Gemeinsamer Bundesausschuss) is the 
highest decision-making body in the 
self-regulation and governance system in 
German health care. Its main responsibility 
is to ensure the implementation of the 
legislator’s demands in every-day practice 
(§ 92, SGB V). Its directives span the areas 
of ambulatory and inpatient care, dentistry 
and psychotherapy, reimbursement and 
provision of diagnostic procedures, 
pharmaceuticals and other therapeutic 
procedures as well as medical devices. 
They are binding once the Federal 
Ministry of Health has approved them. 
The Federal Joint Committee has an 
explicit focus on quality assurance through 
its Quality Assurance Subcommittee. Its 
focal points include mandatory measures 
for quality assurance at the federal level 
and the endorsement of its enhancement, 
internal and external quality control, 
as well as setting minimum volumes 
of services and postgraduate training 
obligations for medical specialists and 
psychotherapists.
Internal and external quality control
Quality control measures differ in 
content, form and enforcement. Quality 
management has been mandatory for 
hospitals since the SHI Reform Act 
of 2000. The Federal Joint Committee 
allows hospitals to choose their quality 
management tool freely, but stipulates 
the aspects to be included. 2  Accreditation 
for hospitals is voluntary. Most hospitals 
that apply for accreditation use the 
Cooperation for Transparency and 
Quality in Health Care (Kooperation 
für Transparenz und Qualität im 
Gesundheitswesen – KTQ) or the proCum 
Cert systems, which rely on an initial stage 
of self-assessment before evaluation by 
external auditors. As of June 2014, there 
were 489 hospitals with a current valid 
KTQ qualification. Interestingly, a survey 
published in 2011 contests the correlation 
between hospital accreditation status and 
patient satisfaction, despite the fact that 
accreditation is widely used as a quality 
endorsement and patient satisfaction is 
stressed in the criteria catalogues of both 
the KTQ and the proCum Cert systems. 3 
Quality elements have also been 
incorporated in the contracting process 
of hospitals. Sickness funds use 
quality indicators to compare hospital 
performance in their negotiations 
with providers. For this purpose, the 
Federal Office for Quality Assurance 
(Bundesgeschäftsstelle Qualität – BQS) 
was established to assist the contract 
partners in choosing and developing 
quality indicators to be monitored as well 
as to collect, compile and analyse the 
data, and to make the findings available to 
individual hospitals in the form of reports 
and recommendations. 4  In 2009, these 
health care-related tasks were transferred 
from the BQS to the AQUA Institute for 
Applied Quality Promotion and Research 
in Health Care.
Additionally, minimum service volumes 
to be provided by hospitals eligible for 
SHI funding were set for certain services 
by the Federal Joint Committee in 2002 
and integrated into the contracting 
process. Contract partners, i.e. the former 
federal associations of sickness funds, 
the German Hospital Federation (DKG – 
Deutsche Krankenhaus Gesellschaft) and 
the Federal Chamber of Physicians, were 
required by law to develop a list of elective 
services (e.g. transplantation and bypass 
surgeries, neonatal intensive care units) in 
which there is a clear positive relationship 
between the volume of services provided 
and the quality of the health outcomes. 
For the services, delivery of a predefined 
minimum volume during the previous year 
has become a precondition for receiving a 
new contract in the next year. 4 
The introduction of DRG-based payments 
for the hospital sector in 2003 highlighted 
the need for better documentation and 
procedure coding, as well as increased 
scrutiny of resource utilisation and 
quality of care. Hospitals are subject to 
external quality control also by means of 
a nationwide reporting mechanism. This 
falls within the remit of the Federal Joint 
Committee and has been implemented 
by the AQUA Institute since 2010. 
Each year, the Federal Joint Committee 
decides on the areas of care to be 
documented. Hospitals are mandated to 
collect information on all cases in these 
areas and send it to AQUA, as well as 
to state-level quality assurance bodies. 
AQUA processes and evaluates data from 
all hospitals and feeds the information 
back to the providers, thus enabling 
them to assess their own performance in 
comparison to others. However, external 
quality control mechanisms could be 
ineffective: a recently published study 
on the development of hospital service 
volumes reveals that the data in hospital 
performance reports often do not conform 
to administrative claims data. For 
example, in the case of hip replacement 
some hospitals reported fewer mortality 
rates than coded in the claims data. 5 
Public reporting
Since 2005, each hospital is obliged to 
publish biannual performance reports 
addressing patients and their relatives but 
also with reference to practitioners and the 
general public. All hospitals contracted 
within the SHI system have to make these 
reports available to the sickness funds for 
online publication and to their visitors in 
hard copies. The reports have to follow a 
uniform structure provided by the Federal 
Joint Committee and include data on 
structure, process and outcomes of care. 
General information on the hospital, its 
administrative organisation and priorities 
need to be covered, as do department-
specific data on diagnoses (following 
the ICD classification) and procedures 
(following the OPS classification). The 
reports also have to include information 
on the hospital’s compliance with external 
control legislation and their participation 
Eurohealth SYSTEMS AND POLICIES
Eurohealth incorporating Euro Observer — Vol.20 | No.3 | 2014
54
in related activities, their achievement 
of minimal volumes and continuing 
education, as well as the types of tools and 
mechanisms they use to enhance quality 
management. However, as mentioned 
earlier, the reports’ accuracy is not subject 
to control mechanisms and, thus, in some 
cases may publish incorrect figures.
‘‘ plans to strengthen quality by lawPublic reporting on hospital performance is primarily based on the official biannual hospital reports, which are used by several platforms. For example, the White List 
(Weisse Liste) is run by the Bertelsmann 
Foundation in cooperation with the 
largest umbrella organisations of patient 
and consumer protection institutions. Its 
search engine allows patients to search 
for providers by diagnosis, intervention 
and geographic area. The indicators 
available for each search depend on the 
condition and/or procedure, but structural 
information, the number of patients per 
physician and nurse and the frequency of 
treatment of similar cases are always in 
place. Data on outcomes are more rare, 
but when available they are presented in a 
traffic-light format (green = within normal 
range/comparable to national average; 
red = beyond expected limits). Similar 
comparison platforms are also run by 
the AQUA Institute and certain sickness 
funds (AOK-Gesundheitsnavigator, TK- 
Klinikführer, Kliniklotse). The reported 
data are sometimes supplemented 
with the experience of the sickness 
funds’ insured. The DKG runs the 
German Hospital Registry (Deutsches 
Krankenhausverzeichnis – DKV), which 
provides the option of searching according 
to quality criteria, documented in hospital 
reports in addition to geographic and 
diagnostic criteria. 6  
Benchmarking
The Federal Ministry of Health widely 
supported the concept of benchmarking 
in inpatient care between 2003 and 2007: 
it endorsed ten model projects that 
aimed to improve inpatient care by 
means of inter-institutional comparisons 
and learning from best practice. An 
evaluation of these projects showed 
varying degrees of development during 
the funding period and no overall trend 
regarding patient outcomes. 7  The Federal 
Association of German Private Hospitals 
(Bundesverband Deutscher Privatkliniken) 
launched a new program for online public 
reporting called Quality Hospitals (www.
qualitaetskliniken.de), which reports on 
clinical quality (process and outcome), 
patient safety and satisfaction as well as on 
the satisfaction of the referring physician. 
It uses administrative data, survey data 
and information from the statutory 
reports of participating hospitals and thus 
provides not only a useful tool for patients 
but also a comprehensive benchmarking 
platform for hospitals themselves. 8  
Another benchmarking approach, based 
on routine data collection and peer 
review, is followed by the Initiative on 
Quality Medicine, which was launched 
as a collaboration between a group 
consisting of private hospitals, charities, 
university departments and not-for profit 
organisations (http://www.initiative-
qualitaetsmedizin.de/). A recent survey 
pinpointed 53 benchmarking initiatives 
with differing levels of adherence to the 
plan-do-check-act (PDCA) cycle active in 
the German health system. 9  
New initiatives
Since the elections in September 2013, 
Germany is governed by a grand coalition 
of Christian and Social Democrats 
with Hermann Gröhe being the Federal 
Minister of Health. The coalition plans to 
strengthen quality by law as an additional 
criterion for decisions on hospital planning 
and payment. The Act to Further Develop 
the Financial Structures and Quality 
in SHI commissions the Federal Joint 
Committee to establish a new independent 
scientific institute: The Institute for 
Quality Assurance and Transparency 
in Health Care. To this end, the Federal 
Joint Committee installed a private-law 
foundation to become the responsible body 
of the new institute and will nominate its 
director (upon approval by the Ministry of 
Health). The institute’s task is to develop 
indicators for quality assurance and 
documentation of quality of care. For this 
purpose, it will be allowed to collect and 
analyse administrative sickness fund data 
and to publish advice.
Although not clearly stated in the Act, 
quality-related payment will receive higher 
priority in hospitals. Plans foresee, for 
example, that hospitals providing high-
quality services could be excluded from 
the 25% payment reduction for increases 
in revenue budgets. Conversely, below 
average quality for individual services 
may, in the future, lead to larger payment 
reductions. Pay-for-performance has 
not yet been formally established in the 
German health system. However, the 
development of comprehensive quality 
assurance indicators stimulates outcome-
related financing and payment for 
the future.
Conclusions
During the last 25 years Germany has 
put more emphasis on quality in the 
inpatient sector. Since the Health Care 
Reform Act of 1989, quality assurance 
measures are a legal obligation and 
through the SHI Reform Act of 2000 and 
the SHI Modernisation Act of 2004, the 
demands placed on quality assurance in 
hospitals and the ambulatory sector have 
been fundamentally revised. The new 
Act to Further Develop the Financial 
Structures and Quality in SHI furthers 
quality assurance in health care, not only 
by making the quality of hospital services 
more transparent for patients, but also 
by establishing a scientific base for the 
introduction of quality-related hospital 
payment. It is worth noting that quality 
assurance mechanisms are important, 
but only as long as they are actually 
used to improve health care quality. A 
potential task for the future Institute for 
Quality Assurance and Transparency in 
Health Care may be not only to develop 
quality measures, but also to monitor their 
implementation and to take action based 
on the results.
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In the German health care system, decision-making powers 
are traditionally shared between national (federal) and state 
(Land) levels, with much power delegated to self-governing 
bodies. It provides universal coverage for a wide range of 
benefits. Since 2009, health insurance has been mandatory for 
all citizens and permanent residents, through either statutory or 
private health insurance. Characteristics of the system are free 
choice of providers and unrestricted access to all care levels. 
A key feature of the health care delivery system in Germany 
is the clear institutional separation between public health 
services, ambulatory care and hospital (inpatient) care. 
Since reunification various governments have implemented 
a number of important reforms in the German health sector, 
including changes in self-governing structures, financing 
the statutory health insurance system, paying providers and 




Vol. 16 No. 2  2014
Health Systems in T
ransition
Reinhard Busse • 
Miriam Blümel 
Today the German health care system has a generous benefit 
basket, one of the highest levels of capacity as well as modest 
cost-sharing. Expenditure per capita is high and access is 
good. However, the system also shows areas in need of 
improvement when compared to other countries and has low 
satisfaction figures with the health 
system in general and issues 
around quality of care, if the 
outcomes of individual illnesses 
are analysed. 
This new health system review 
(HiT) on Germany examines 
changes and reforms that have 
taken place and discusses 
challenges for the new 
government that came to power 
at the end of 2013.
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Health and safety at work: Strategic 
Framework sets out EU objectives 
for 2014 – 2020
On June 6 the European Commission 
published a new Strategic Framework on 
Health and Safety at Work 2014 – 2020. 
It identifies three key challenges:
1.  To improve implementation of existing 
health and safety rules, in particular by 
enhancing the capacity of micro and 
small enterprises to put in place effective 
and efficient risk prevention strategies
2.  To improve the prevention of work-
related diseases by tackling new and 
emerging risks without neglecting 
existing risks
3.  To take account of the ageing of 
the EU’s workforce.
A number of different proposed 
strategic actions are set out to meet 
these challenges. They include further 
consolidating national health and safety 
strategies through, for example, policy 
coordination and mutual learning. Further, 
the framework recommends simplifying 
existing legislation where appropriate 
to eliminate unnecessary administrative 
burdens, while preserving a high level of 
protection for workers’ health and safety. 
The importance of the enforcement of 
health and safe workplaces is made clear, 
with one proposed suggestion being to 
evaluate the performance of national labour 
inspectorates. Other actions include the 
provision of practical support to small 
and micro-sized business to help them 
to better comply with health and safety 
rules, including the use of web based 
risk assessment tools. The framework is 
also mindful of the need to take account 
of the ageing of the European workforce 
and to improve the prevention of work-
related diseases. It also recognises the 
importance of developing better monitoring 
tools and reinforcing coordination with 
international organisations (such as the 
International Labour Organisation, the 
World Health Organization (WHO) and 
the Organisation for Economic Co-
operation and Development.
The new Strategic Framework builds on 
the 2007 – 2012 EU Occupational Health 
and Safety (OHS) Strategy. 27 Member 
States now have a national OHS strategy, 
adapted to the national context and key 
priority areas. The new framework will be 
reviewed in 2016 in order to take stock of 
its implementation and to take into account 
the results of an on-going comprehensive 
evaluation of EU occupational health and 
safety legislation which will be available 
by the end of 2015.




WHO calls for stronger action on 
climate-related health risks
Measures to adapt to climate change could 
save lives around the world by ensuring 
that communities are better prepared 
to deal with the impact of heat, extreme 
weather, infectious disease and food 
insecurity. For example, changes in energy 
and transport policies could save millions of 
lives annually from diseases caused by high 
levels of air pollution. The right energy and 
transport policies could also reduce the 
burden of disease associated with physical 
inactivity and traffic injury. These were key 
messages discussed at the first-ever global 
conference on health and climate, which 
took place at WHO headquarters in Geneva 
from 27 to 29 August. The conference 
brought together over 300 participants, 
including government ministers, heads 
of UN agencies, urban leaders, civil 
society and leading health, climate and 
sustainable-development experts.
The environment and health sectors in the 
WHO European Region have a long history 
of collaboration, consolidated in 2010 
through the establishment of the European 
Environment and Health Ministerial Board. 
Participants from the WHO European 
Region participated in sessions on policies, 
mechanisms and tools for building health 
resilience to climate change, issues 
in urban settings and the leveraging 
of environment and climate finance to 
strengthen health systems. European 
Working Group on Health in Climate 
Change (HIC) co-chairs, Louise Newport of 
the Department of Health, United Kingdom, 
and Jutta Litvinovitch of the Federal 
Ministry for the Environment, Nature 
Conservation, Building and Nuclear Safety 
in Germany, made a statement stating that 
“climate change responses have been 
rather reactive, as was seen recently in 
the multiple floods hitting Europe this year. 
Advance planning for what climate change 
will likely bring is an important component 
of the health-in-climate-change response, 
so capacities need to be evaluated and 
actively developed.” The conference 
aimed to pave the way for consideration 
of health and climate issues in the 
UN Climate Summit, held in New York 
on 23 September 2014.
More information at: http://www.who.int/
globalchange/mediacentre/events/climate-
health-conference/en/
New report: preventing suicide a global 
imperative
On 4 September WHO published 
“Preventing suicide: a global imperative”. 
It reviews current data on suicide attempts 
and mortality. The report notes that 
suicide accounts for 17.6% of all deaths 
among people aged 15 – 29 years in high-
income countries and is thus a leading 
cause of death among people in this age 
group. Globally, 8.5% of deaths among 
young adults are due to suicide. The 
WHO European Region includes 33 of 
the 54 high-income countries identified 
in the report and tackling suicide is a key 
element of the WHO Euro’s Mental Health 
Action Plan and the European Commission 
supported Joint Action on Mental Health 
and Wellbeing.
The new report is available at: 
http://tinyurl.com/ose3ser
The European Mental Health Action Plan is 
available at: http://tinyurl.com/kby82ma
The Joint Action on Mental Health and 
Wellbeing is available at: http://www.
mentalhealthandwellbeing.eu/
Additional materials supplied by:
EuroHealthNet
6 Philippe Le Bon, Brussels.
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